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2PREFACE.
This Thesis describes a group of studies carried out 
during my appointment as a Research Fellow at the Gastro­
enterology Unit, Royal Infirmary, Glasgow. Parts of this 
work were published and others are being considered for 
publication. Reprints, where available, are submitted 
with the Thesis. Some of the work described was also 
presented to learned societies.
The help and contribution of a number of colleagues 
and co-workers are formally acknowledged. Except where 
indicated, the work and writing of this Thesis has been 
personally carried out by me.
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Gastric acid has always been recognized as a 
major factor in the pathogenesis of peptic ulcer disease. 
Recently, it has been suggested that three more factors 
are likely to influence the natural history of peptic 
ulceration: prostaglandins (PGs), non-steroidal-anti-
inflammatory drugs (NSAIDs), and Helicobacter pylori (H. 
pylori).
Despite the widespread recognition of the 
potentially useful properties of PGs, the methodology 
used in their research has often given rise to conflicting 
and irreproducible results. Apart from the type of assay 
used (e.g. bioassays, radioimmunoassays, gas 
chromatography - mass spectroscopy), the method of 
handling the tissues prior to the assay is likely to
affect their potential to synthesise PGs. Evidence is 
presented in this Thesis, that freezing gastric and
duodenal biopsies alters their ultrastructure and capacity 
to synthesise PGs. When paired gastric and duodenal
biopsies were studied (each pair consisted of one fresh
and one frozen biopsy), it was found that freezing 
resulted in disintegration of the cell membranes of all 
the cells within the individual biopsies. Specimens
incubated after having been frozen, produced more PGE2 and 
PGI2 than their fresh counterparts. This could be due to 
the availability of more PG precursors derived from the 
cell membranes which have been damaged by the effect of 
freezing. Compared to 67% cytolysis produced by some 
ordinary homogenizers, freezing seems to be a more
24
convenient and effective method of homogenization, since 
it causes damage of 100% cells in biopsies destined for PG 
measurements. In the absence of general guidelines as to 
whether biopsies should be processed fresh or after 
freezing them in the context of PG measurements, the above 
findings would help understand the consequences of both of 
these options.
In recent years diet has emerged as being able 
to affect gastric mucosal PG synthesis, and as a result, 
the capability of the mucosa to defend itself against 
injurious agents. Most experiments have used individual 
polyunsaturated fatty acids like arachidonic acid and 
linoleic acid. It was not clear if these acids would 
still stimulate gastric PG synthesis if given as 
components of oil diets that also contain other fatty 
acids capable of inhibiting the cyclo-oxygenase pathway, 
such as eicosapentaenoic acid. This issue is addressed 
in this Thesis by studying gastric tissue PG synthesis in 
four groups of male Lewis rats which were fed for six 
weeks on fat-free diet (control group), 7% fish oil diet, 
7% evening primrose oil diet, and 7% olive oil diet. 
Gastric PGE2 was higher in rats taking any of the oil 
diets studied as compared to the control group. Olive 
oil diet induced the production of more PGE2 than fish 
oil, which was found to contain a significant proportion 
of the inhibitory acids, eicosapentaenoic acid and 
clupanodonic acid (docosahexaenoic acid). Given the
cytoprotective characteristics of PGs, these results
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indicate that diets rich in the above oils would help the 
gastric mucosa maintain its integrity. If such findings 
could be confirmed in man, they might be relevant to the 
understanding of the incidence of peptic ulceration in 
those areas in the world where olive or fish oils 
constitute part of the local staple diet.
the relationship between duodenal mucosal PG 
synthesis and duodenal ulcer formation remains 
controversial since some studies showed deficiency in PG 
synthesis, while others did not. The situation has been 
further complicated by the failure of PG analogues to make 
a significant impact in the treatment of duodenal ulcers 
when compared to H^-antagonists. The state of duodenal 
PG synthesis is re-examined in this Thesis in a group of 
patients with duodenal ulcers. The results show no
evidence of any deficiency in PGE2 , PGl2» or thromboxane 
B2 in duodenal biopsies taken from patients with duodenal 
ulcers, as compared to a group of control subjects without 
ulcers. The failure of duodenal mucosal PGs, in duodenal 
ulcer patients, to rise in response to the challenge with 
an acid load shown by a previous study, is probably more 
important than their basal PG values.
There is a continuous demand for an 
alternative anti-inflammatory therapy with fewer gastric 
side effects, especially in patients with chronic diseases 
like rheumatoid arthritis. Endoscopy is probably one of 
the most, if not the most, reliable means of monitoring 
the side effects of NSAIDs on the gastric and duodenal
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mucosa. Such procedure will have to be used at one stage 
or another in the course of the proper assessment of the 
gastro-duodenal side effects of NSAIDs, especially the 
newer preparations. The efficacy of one of the new 
NSAIDs, etodolac, and its effect on the gastro-duodenal 
mucosa as judged by endoscopy, are studied in this Thesis 
in a group of patients with active rheumatoid arthritis, 
as compared to naproxen which has an established record in 
the treatment of arthritic diseases. After four weeks of 
treatment both agents appeared to have a comparable 
efficacy. Endoscopic abnormalities developed in a
greater number of patients taking naproxen, who also had 
significantly worse endoscopic scores. Most lesions were 
asymptomatic, and the gastric antrum was mainly affected 
especially in smokers.
Another study in this Thesis investigates the 
possibility that the differences between naproxen and 
etodolac on the gastric and duodenal mucosa are related to 
their effects on mucosal PG synthesis. PG values were 
measured at baseline and after four weeks of taking either 
agent in therapeutic doses by patients with active 
rheumatoid arthritis. Naproxen suppressed gastric PGE2 , 
duodenal PGE2 and PGI2 , while etodolac did not. The fact 
that naproxen caused a greater number of endoscopic 
abnormalities might therefore be related to its effect on 
gastric and duodenal PG production, but the study found no 
correlation between PG values and endoscopic scores. 
Also, patients taking etodolac who developed evidence of
27
gastric damage, showed no significant change in their 
mucosal PG synthesis. This study, which is unique in 
being the first to assess the effect of individual NSAIDs 
on gastric and duodenal tissue PGs in rheumatoid patients, 
shows that not all NSAIDs suppress gastric or duodenal PG 
production. Other mechanisms of mucosal damage by NSAIDs 
need to be considered in addition to their effects on PGs.
While PGs are known for their favourable 
properties in relation to the gastrointestinal mucosa, 
Helicobacter pylori (H. pylori) has been linked to the 
development of gastritis and peptic ulceration. It is
not clear whether an interaction exists between PGs and 
H. pylori. This subject is considered by a study in this 
Thesis in which the presence of H. pylori is determined by 
both histology and bacteriology in patients with antral 
gastric ulcers (GU) and non-ulcer dyspepsia (NUD). PGs 
are measured in biopsies taken from the antrum, and at 
least 2 cm away from the ulcer edge in GU patients. In 
line with previous findings, this study shows that H. 
pylori is associated with a significant number of cases 
with GU or active chronic gastritis. Also PG values are 
higher in patients with severe gastritis or GU than those 
with mild gastritis or NUD, when the presence of H. pylori 
is disregarded. Surprisingly, there is no significant 
difference between PG values in patients infected with H. 
pylori or those free of the organism, despite the 
presence of a greater number of cases with gastritis in 
the infected group. These findings might encourage
28
speculation about the presence of at least a partial 
defect in PG production at the level of the mucosal cells 
or the neutrophils, which can also synthesise PGs. 
However, the presence of such defect is not confirmed by 
this study.
The understanding of the activity of H. pylori 
was enhanced by the findings of Leunk et al. in 1988, 
which suggested that H. pylori culture filtrates contained 
a factor cytotoxic against Vero (mammalian) cell lines. 
The effect of this factor on the human gastric mucosa or 
its possible interaction with another mucosal damaging 
agent, indomethacin, are not clear. These points are 
addressed by another study in this Thesis. The
combination of H. pylori culture filtrate and indomethacin 
reduces mucosal PGE2 production and the histological 
scores to a greater extent than indomethacin alone, in 
vitro. This might indicate the presence of an
interaction between indomethacin and H. pylori culture 
filtrate. Such interaction appears to be damaging to the 
human gastric mucosa.
Many studies have attempted to establish a 
link between H. pylori and the development of structural 
damage to the gastro-duodenal mucosa. The possible
effect of the organisms on the function of the gastric 
mucosa is not fully understood. A protein isolated from 
H. pylori culture filtrates inhibited acid secretion by 
rabbits parietal cells, as shown by Cave and Vargas in 
1989. Cyclic AMP acts as a second messenger for several
29
physiological activities in the gastric mucosa, including 
acid secretion. In this Thesis, H. pylori protein is 
isolated from the culture filtrates, and its effect on 
c.AMP production investigated. H. pylori protein is
shown to suppress the generation of c.AMP in the fundic 
mucosa in vitro, intensify its inhibition by indomethacin 
and prevent its stimulation by histamine. This might 
explain the acid inhibitory effect of H. pylori protein. 
It also suggests that this protein has the potential to 
interfere with other physiological activities mediated by 
c.AMP.
SECTION 1
BACKGROUND OF THESIS.
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INTRODUCTION.
The understanding of the pathogenesis of peptic ulcer 
disease has been aided by the recent identification of 
three major factors: prostaglandins, non-steroidal anti­
inflammatory drugs, and Helicobacter pylori. This
Thesis contains a group of studies covering certain 
aspects related to these topics. Prostaglandin
measurements are common to all sections of this Thesis.
Section 1 reviews past and recent findings in the 
areas under discussion. It also describes methods and 
techniques common to various studies in this Thesis. 
These include prostaglandin radioimmunoassay,
identification of H. pylori, preparation of H. pylori 
culture filtrate, and isolation of H. pylori protein. 
This section ends with a summary of the aims of this 
Thesis.
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CHAPTER 1.
1. CHEMISTRY AND PHARMACOLOGY OF PROSTAGLANDINS.
1.1. INTRODUCTION AND HISTORICAL BACKGROUND.
Prostaglandins (PGs) constitute a family of 
chemically related fatty acids that are among the most 
prevalent naturally occurring compounds; they seem to 
modulate many biological functions in the body. They are 
formed by a complex of microsomal enzymes, acting on 
certain 20-carbon unsaturated fatty acids, particularly 
eicosatetraenoic or arachidonic acid (AA). Additional 
products of the cellular metabolism of AA, differing in 
structure from PGs, include the thromboxanes (TX) and 
leukotrienes (LT), whose physiological and pathological 
functions are closely interrelated with those of the PGs.
The existence of the PGs has been known for over half 
a century. Kurzok and Lieb (1) were the first to
observe, in 1930, that strips of human uterus relax or 
contract when exposed to human semen. In the mid 1930s, 
von Euler (2) in Sweden and Goldblatt (3) in England 
independently extracted crude PGs from the seminal fluid 
of man and vesicular glands of sheep, and reported their 
smooth-muscle-contracting and vasodepressor activities. 
In the late 1950s, Bergstrom and Sjovall (4) isolated PGs 
in a pure form and, in the early 1960s, determined their 
chemical structure. With the identification of two
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unstable cyclic endoperoxides, PGG2 (5) and PGH2 (6), the 
emphasis shifted from the primary PGs (E and F series) to 
other biologically active products of AA metabolism, 
resulting in the discovery of TXA2 (7) and prostacyclin, 
PGI2 (8). In addition to the cyclo-oxygenase mechanism, 
another metabolic pathway, converting AA to hydroperoxides 
(HPETE and HRTE) (9,10) and then to LTs (11) was
identified. The impact of PGs and other products of AA 
metabolism could be compared only to that of
corticosteroids in the late 1940s and 1950s.
1.2. CHEMICAL STRUCTURE AND BIOSYNTHESIS.
The natural PGs are considered analogues of
prostanoic acid, a structure with a 20-carbon and 5- 
membered ring. They fall into several classes designated 
by letters, indicating different substituents on the ring, 
alphabetically, in order of their discovery. The main 
classes are subdivided according to the number of double 
bonds on the side chain indicated by the subscript 1,2 or 
3.
The common precursors of PGs, TXs, and LTs are three 
naturally occurring eicosapolyenoic acids: trienoic
(dihomo-^-linolenic) acid, tetraenoic (arachidonic) acid 
(AA) and pentaenoic acid (12). In man, tetraenoic acid 
(AA) is by far the most common, giving rise to the PGs of 
the subscript-2 series. It is either derived from
dietary linoleic acid or ingested as a constituent of 
food. After absorption from the gut, it is esterified
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and presents ubiquitously in the body as a component of 
phospholipids of cell membranes and other complex lipids.
The hydrolysis of esterified AA provides the first 
rate-controlling step in PG formation. Dihomo- -
linolenic acid, which has one less double bond than AA, 
gives rise to PGs of the subscript-1 series. Pentaenoic
acid is very rare, derives from fatty acids with three
double-bonds, and is converted to PGs of the subscript-3
series.
In mammalian tissues, PGs and their precursor acids 
occur in appreciable quantities only in seminal, menstrual 
and amniotic fluids. The precursor acids are present as 
phospholipids in cell membranes. A wide variety of
divergent physical, chemical, and neurohormonal factors 
may activate the enzyme phospholipase A2 , setting free the 
precursor acids to gain access to enzyme complexes present 
in most tissues. Once released, fatty acids can follow 
two pathways: the cyclo-oxygenase pathway gives rise to
the PGs and TXs, while the lipoxygenase pathway gives rise 
to the LTs and other unsaturated hydroxy acids. The 
metabolic pathway for AA and the structures of selected 
metabolites are shown in Figure 1.
The chain of events leading to the release and 
metabolism of AA from the membrane phospholipids can be 
initiated by a number of factors: nerve stimulation,
neurotransmitters (e.g. norepinephrine), neuropeptides 
(e.g. somatostatin), various humoral agents (e.g.
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bradykinin), hyperosmolar solutions and even mechanical 
strain. Indeed, almost any deformation of cell
membrane,such as stretching a blood vessel, inflation of 
the lungs or contraction of the intestine, may lead to 
increased PG formation under physiological conditions (13- 
15). Numerous pathological conditions may increase PG 
and TX synthesis. Any damage of tissue, apart from frank 
trauma, increases the generation of cyclo-oxygenase 
products (16). Acute cardiac ischaemia favours the
synthesis of vasoconstrictor products over normal 
vasodilator metabolites of AA. Tissue injury from an 
anaphylactic reaction or oedema may augment PG formation 
(e.g. in the lungs) and may contribute to vascular 
permeability. Acute hypoxia or exposure to tobacco smoke 
in the lungs also increases PG synthesis.
Thus, many kinds of tissue injury may lead to 
increased generation of PGs and LT products (17). 
Breakdown of lysosomes will release, among other enzymes, 
phospholipases, which may hydrolyse AA from the membrane 
phospholipids.
Not all metabolites are formed in every tissue when 
AA is released; it depends on the most active enzymes in 
the tissue involved. All cells contain phospholipids and 
at least some cyclo-oxygenase and lipoxygenase. Most 
tissues seem able to synthesise PG endoperoxides from free 
AA, but the factors controlling their further steps have 
not been defined. Certain tissues (such as lung, spleen, 
gastrointestinal tract, thyroid and adrenals) are able to
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synthesise the whole range of products, whereas other 
tissues predominantly produce PGD2 (mast cells), PGE2 
(seminal vesicles), PGI2 (vessel wall) or TXA2 
(platelets).
Products of lipoxygenase are direct inhibitors of the 
cyclo-oxygenase pathway, suggesting the existence of a 
negative feedback relationship between these two pathways. 
Similarly the inhibition of TX biosynthesis (e.g. by 
imidazole derivatives) leads to increased formation of 
primary PGs (18).
The PG intermediates, PGG2 and PGH2 , are highly 
unstable, apparently existing only momentarily in vivo. 
PGs are rapidly inactivated, the first step being the 
oxidation of the C-15 hydroxyl group by 15-hydroxy-PG- 
dehydrogenase (PGDH). This enzyme is widely distributed 
in many tissues, especially the lungs; consequently, about 
95% of PGs of the E and F series, but not D or I, are 
metabolised during a single passage through the lungs. 
The 15-keto compound is then reduced by a reductase 
enzyme (PGR) to the 13,14-dihydro derivatives. 
Subsequent beta-oxidation and omega-oxidation of the side- 
chains causes further degradation, giving rise to 
dicarboxylic acids in the urine. Both PGDH and PGR are 
intracellular soluble enzymes, so that the substrate must 
pass through the cell membrane before degradation can 
proceed. Natural PGE2 and PGF2 pass through the
membrane and are quickly inactivated. In contrast,
methylated PGs (e.g. 16, 16-dimethyl PGE2 ) also cross the
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membrane but are not the substrate for PGDH; therefore, 
they are not taken up by the lung tissue and then slowly 
released unchanged into the circulation. This results in 
prolonged biological activity. PGl2> which is the
substrate for PGDH in vitro but not for transfer into lung 
cells, can pass unchanged from the venous to the arterial 
blood. Such selectivity in PG inactivation is not seen 
in the gastrointestinal mucosa or in the liver, where all 
natural PGs are inactivated on passage through the portal 
circulation. However, methylated PGs can escape
inactivation, being resistant to the mucosal or hepatic 
PGDH; they are active orally and , in part, act from the 
gastric lumen directly on the gastric glands. PG1)2 an(* 
TXA2 are not degraded by PGDH, although they possess a 15- 
hydroxyl group. TXA2 is very unstable and spontaneously 
converts to TXB2 , which follows the catabolic route of 
other PGs. PG12 also hydrolysed spontaneously to
inactive 6-keto-PGF^
1.3. PHYSIOLOGICAL AND PHARMACOLOGICAL ACTIVITIES.
PG-mediated control of cellular, tissue or organ 
functions reflects the interactions between different PGs, 
TXs and LTs; this might explain why some PGs have directly 
opposing actions in many systems.
1.3.1. The Gastrointestinal Tract - Introduction.
PGs of the E,F and I series are synthesised in 
substantial amounts throughout the gastrointestinal tract 
(19,20). There are marked species differences in the
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generation of various types of PGs. Quantitatively, the 
predominant form of PGs in human, feline and canine 
gastric mucosa seems to be PGE2 (21), whereas it is PGI2 
in the rat’s mucosa (20).
PGs are released under various conditions, such as 
neurohormonal stimulation of digestive gland secretion, 
mechanical strain on the gut wall, action of various 
humorals (acetylcholine, norepinephrine, angiotensin, 
bradykinin, histamine, etc.), and the presence of 
hyperosmolar solutions or other irritants in the gut lumen 
( 22) .
1.3.2. Effects on Gastric Secretions.
PGs of the E and I series inhibit basal and 
stimulated gastric acid secretions both in vitro and in 
vivo. In the dog, either PGE2 or PGI2 inhibits gastric 
acid secretion stimulated by food, histamine, 
pentagastrin, 2-deoxyglucose, carbachol or reserpine 
(23,24). PGI2 was found to be several times more potent 
than PGE2 in inhibiting acid secretion when given 
intravenously (25). With direct intra-arterial
administration, PGE2 is a more potent inhibitor than PGI2 , 
and, in contrast to PGI2 , causes a reduction in mucosal 
blood flow (26). Methyl analogues of PGE2 were found to 
be many times more potent than native PGE2 in inhibiting 
gastric acid secretion in animals and in humans. The 
gastric inhibitory effect of natural PGs and their 
methylated analogues has been confirmed in humans. PGE^
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and PGE2 are reportedly inactive when given orally and are 
capable of inhibiting histamine- and pentagastrin-induced 
acid secretion only when infused intravenously (27,28). 
PGE2 was later reported to cause a moderate inhibition of 
gastric secretion when given orally in larger doses (29). 
In contrast, methyl PGE2 analogues were found to be active 
gastric inhibitors after either intravenous or oral 
administration (30). Their prolonged inhibitory effects 
on basal and pentagastrin- or meal-stimulated gastric 
secretion were observed in healthy subjects, in peptic 
ulcer patients, and in patients with Zollinger-Ellison 
syndrome.
The mechanisms by which natural PGs and their 
analogues inhibit gastric acid secretion is still unclear. 
The possibility of direct inhibition of parietal cells by 
methyl PGE2 analogues acting from the gastric lumen is 
supported by the finding that these agents are capable of 
inhibiting acid formation in isolated parietal cells, in 
gastric glands and in isolated gastric mucosa (31). PGE2 
analogue was more effective after topical application to 
the human gastric mucosa than intraduodenal or jejunal 
administration (32).
The antisecretory PGs probably operate via special 
membrane receptors to reduce the formation of cyclic AMP 
in the parietal cells. They decrease histamine-
stimulated accumulation of cyclic AMP in the parietal 
cells as well as the secretory activity of these cells. 
They appear to block the stimulatory action of histamine
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on cyclic AMP synthesis, thus removing the major pathway 
for the excitation of parietal cells by histamine and 
other interacting secretagogues such as acetyl choline or 
gastrin (33,34).
Another mechanism through which PGs might affect 
gastric secretion is suppression of gastrin release. 
Methyl PGE£ analogues given orally caused a marked 
suppression of gastrin response to a meal (30).
PGs, and particularly their methyl analogues, when 
applied topically to the gastric or duodenal mucosa, 
stimulate mucus-alkaline secretion; this may account, at 
least in part, for the reduction in luminal acidity 
observed with administration of these PGs. It may also 
contribute to the enhancement of mucosal protection (35- 
37). In contrast to the mucosal alkaline secretion, PGs 
reduce bicarbonate secretion by the pancreas. PGI2 
particular was shown to reduce the stimulated pancreatic 
secretion of bicarbonate"and protein enzymes (31).
1.3.3. Mucosal Protection (Cytoprotection).
PG analogues, when given topically or parenterally in 
non-anti-secretory doses, are capable of preventing the 
gross mucosal lesions of the stomach and intestine 
resulting from exposure to various ulcerogens and 
irritants (38). This protection can be reproduced by 
intragastric administration of lower concentrations of
damaging agents (e.g. 20% ethanol or 5 mM taurocholate). 
Since these "mild irritants" enhance mucosal PG
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biosynthesis, it is likely that their protective action is 
mediated by endogenous PGs (38-40).
The term cytoprotection is now quite popular in 
medical literature; however, PGs and mild irritants do not 
completely protect the mucosa from damage by necrotizing 
agents. It appears that the mucosa exposed to a
necrotizing agent (whether or not pretreated with PG) 
undergoes extensive damage in the surface epithelium, 
which is exfoliated and replaced by epithelial cells 
migrating from the gastric pits. PGs do, however,
protect the deeper mucosal layers, thus facilitating 
prompt recovery of the mucosa. It is likely that the 
protection by PGs against gastric mucosal bleeding from 
NSAIDs or ethanol, and speeding of the healing rate of 
gastroduodenal ulceration in humans are due, at least in 
part, to the protective properties of PGs.
Cytoprotection is probably not limited to the 
gastrointestinal mucosa; damage to other digestive organs, 
such as the liver and the pancreas, can also be reduced by 
certain PGs (31).
The nature of cytoprotection is unknown but several 
mechanisms have been postulated, including an increase in 
mucus-alkaline secretion (35,36), enhancement of mucosal 
blood flow, and stabilization of lysosomal membranes 
coupled with a reduction in the release of lysosomal 
enzymes (41). It has also been suggested that PGs
maintain the hydrophobicity of mucosal surface and reverse
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the reduction of this hydrophobicity by damaging agents 
such as aspirin (42). Similar effects have been obtained 
using phospholipids with surfactant properties (43).
1.3.4. Effects on Intestinal Contractility, Secretions
and Blood Supply.
Exogenous PGs exhibit a considerable variability in 
their action on intestinal smooth muscle, depending on the 
type of PG, the dose, and the muscle layer studied. In 
general, PGs of the E and I series inhibit, whereas PGs of 
the F series stimulate intestinal contractility (44).
PGE and its methylated analogues strongly stimulate 
intestinal fluid and electrolyte accumulation in the gut 
lumen (enteropooling), which may result in diarrhoea (45). 
PGs of the I series exert the opposite effect, reducing 
the enteropooling action of the E series (46). Diarrhoea 
is one of the major side effects occurring in patients 
treated with PGE and its stable analogues (47).
PGs appear to play an important role in the 
regulation of the gastric circulation and can alter 
gastric blood flow either by a direct effect on the 
vascular smooth muscle or, indirectly, by action on the 
other gastric functions. Systemic or local infusion of 
PGs of the E and I series or their stable analogues 
results in an increase in basal gastric blood flow; in 
contrast, when given during stimulated gastric secretion, 
they may decrease blood flow as a consequence of the 
inhibition of gastric acid secretion (22,23). Since
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aspirin and indomethacin decrease total gastric blood 
flow, which is mainly confined to the mucosal-submucosal 
layer, it has been suggested that local PGs in the gastric 
wall are important in the control of gastric blood flow 
(48,49).
Arachidonic acid and PGs of the E and I series 
infused into the superior mesenteric artery produced a 
marked intestinal vasodilation, whereas the inhibitors of 
cyclo-oxygenase show opposite effects (25,50). The same 
series also increases oxygen consumption in the gut, 
probably due to stimulation of intestinal transport 
processes (22). F series PGs constrict the intestinal 
vascular bed and reduce oxygen consumption. Results of 
studies using pharmacological doses of PGs indicate that 
they play an important role in the regulation of resting 
blood flow and the vascular responses to food (48-50).
Because of their gastric antisecretory and mucosal 
protective properties, PGE2 and its methylated analogues 
have been tried in peptic ulcer therapy (51,52) and in the 
prevention of gastric toxicity of NSAIDs (47). The 
results of these clinical trials indicate that PGs are 
superior to placebo in accelerating ulcer healing or in 
ulcer prevention; however, side effects, particularly 
diarrhoea limit their wider clinical use.
1.4. THE ROLE OF DIETARY FATTY ACIDS IN PG PRODUCTION.
In addition to their effect on PG production, 
polyunsaturated fatty acids in general and omega-3 fatty
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acids in particular are thought to affect a wide range of 
biological processes. They are largely derived from
marine animals, and differ from the 18-carbon unsaturated 
fatty acids common in Western diets (linoleic and oleic 
acids) in that their first double bond is located between 
the third and fourth carbon atoms from the methyl end 
(hence the designation N-3 or omega-3). The two major 
omega-3 fatty acids are eicosapentaenoic acid (C20:5, 
omega-3) with five double bonds and docosahexaenoic acid 
(C22:6, omega-3) with six double bonds. Major effects of 
these fatty acids include reduction of plasma triglyceride 
and lipoprotein levels (53,54), reduction of 
thrombogenecity of platelets in the microcirculation (55) 
due to effects on the mediators derived from arachidonic 
acid (56), altered inflammatory and immune cell function 
(57), and retarded development of atherosclerosis (58).
As for their effect on the gastric mucosa, 
polyunsaturated fatty acids (linoleic and arachidonic 
acids), when given to experimental animals, result in 
increases in PG concentrations in gastric juice (59,60) 
and these prevent experimental mucosal injury (60). It 
is unclear, however, whether gastric PG production can 
still be increased by linoleic or arachidonic acids when 
given as part of naturally occurring oils that also 
contain other fatty acids like eicosapentaenoic acid and 
docosahexaenoic acid which competitively inhibit the 
utilization of arachidonic acid and its precursors by 
cyclo-oxygenase (12,61,62).
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One of the studies included in this Thesis (Chapter
7) shows that gastric tissue PGE2 is higher in rats fed on 
diets containing fish oil, evening primrose oil and olive 
oil, compared with controls. Also animals fed on fish 
oil tend to have lower PGE2 values than those fed on olive 
oil or evening primrose oil. Gas-liquid chromatography 
conducted on these three oils demonstrates that fish oil 
contains large amounts of eicosapentaenoic and 
docosahexaenoic acids. The inhibitory effects of these 
acids on the cylclo-oxygenase system (12,61,62) might 
help explain the tendency of gastric PGE2 to be low in 
animals fed on fish oil. Hollander and Tarnawski (63) 
have recently suggested that the marked increase in the 
dietary availability of essential fatty acids could be 
responsible at least in part for the decrease in the 
incidence of peptic ulcers in the Western world. This 
could be due to the potential of these diets to stimulate 
the synthesis of mucosal .PGs, especially of the E2 series 
(63).
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CHAPTER 2
2. PROSTAGLANDIN PRODUCTION IN PEPTIC DISORDERS.
MEASUREMENTS AND POSSIBLE SOURCES OF CONFLICT.
2.1. INTRODUCTION.
The finding by some early workers (64,65) of reduced 
PG synthesis in patients with gastric ulcers had 
encouraged hopes of devising a therapeutic approach based 
on treating a deficiency state. The attractions of such 
an approach stem from the possibility that it would be 
physiological, and as a result, less likely to have 
serious side effects. Numerous other publications have 
documented that NSAIDs caused both PG inhibition and 
gastric damage. This might have contributed to the early 
impression that peptic disease, in general, was associated 
with PG deficiency. However, no conclusive evidence has 
been shown to prove that a correlation existed between PG 
inhibition by NSAIDs and the degree of mucosal damage. 
Opinions have, therefore, varied as to whether PG 
synthesis was inhibited, un-altered, or increased in 
various peptic disorders. In addition to the influence 
of NSAIDs, several other factors need to be considered 
when PG production is assessed. Such factors, discussed 
below, can probably account for many sources of conflict 
in the reported PG measurements.
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2.2. PROSTAGLANDIN MEASUREMENTS IN PLASMA AND GASTRIC 
JUICE.
In 1974, Hindsale et al. (66) measured PGE in plasma 
and gastric juice, and found that PGE was significantly 
lower in duodenal ulcer patients, in the basal state, 
than in normal volunteers. Plasma PGE was also higher 
during stimulation with betazole. Such findings were 
disputed by Tonnesen et al. (67) and Baker et al (68) who 
found that PGE and acid output were higher in patients 
with duodenal ulcers. In a more comprehensive study, 
Baker and colleagues (69) measured plasma concentrations 
of PGE and PGF in patients with gastric ulcers, duodenal 
ulcers and in subjects without ulcers. No deficiency in 
plasma PG levels was found. Also, plasma PG
concentrations failed to correlate with the parameters of 
gastric secretion studied, and were unaffected by
histamine I^-receptor blockade or the activity of duodenal 
ulceration. During combined pentagastrin and insulin 
secretory studies, the same authors (69) found a 
significant correlation between the outputs of PGE and
acid into gastric juice.
The rapid clearance of PGs from the circulation, up 
to 90% in a single passage through the lungs and liver 
(70,71) make it unlikely that changes in gastric PG
metabolism will be reflected in the plasma or that plasma 
PG levels will influence gastric secretory status, with 
the exception of relatively large PG infusions.
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As PGs are synthesised and can be inactivated within 
the same tissues (72,73), and are rapidly cleared from the 
circulation, it is likely that their action is a local 
one. Variations in the gastric output of PGs occur under 
different conditions (74) and it seems reasonable to 
speculate that changes in gastric mucosal PG metabolism 
will be more likely to be paralleled by changes in the 
gastric juice than in plasma PG levels.
In conclusion, PG concentrations in gastric juice or 
plasma may be misleading, as mucosal events may not be 
reflected temporally and PGs themselves are unstable. 
Moreover, the anatomic origin of PGs, especially those in 
plasma, is uncertain.
2.3. MEASUREMENT OF PROSTAGLANDINS IN GASTRIC AND 
DUODENAL TISSUE.
2.3.1 Prostaglandin Synthesis in the Presence of 
Ulceration.
Several studies have measured PG synthesis in gastric 
ulcer mucosa. Konturek et al. (64) found decreased PG 
values and this was in agreement with previous findings by 
Wright et al. (65). Other workers (75), on the other 
hand, could not detect any significant differences in PG 
synthetase activity in gastric mucosal biopsies from 
patients with inactive gastric ulcer and those from either 
healthy controls or patients with inactive duodenal ulcer. 
Work presented in this Thesis (Chapter 11) shows that PGE2 
synthesised by gastric mucosal specimens is higher in
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patients with gastric ulcers than those with non-ulcer 
dyspepsia. This is probably due to the effects of
gastritis, discussed below.
Some of the studies employing the technique of 
cultured mucosal biopsies have shown that PG production in 
duodenal mucosa from patients with duodenal ulcers is not 
impaired (76). Biopsies from gastric mucosa obtained from 
the same patients showed reduced PG production (76). 
This finding of an abnormality in gastric but not in 
duodenal mucosa in duodenal ulcer patients, is difficult 
to interpret. Another study (77) suggested that duodenal 
PGI2 synthesis was defective in duodenal ulcer patients. 
The presence of such a defect could not be confirmed by 
the findings of a study presented in this Thesis (Chapter
8). Other workers (64) found no difference in gastric 
mucosal PG content in patients with duodenal ulcer or 
healthy volunteers. However, when the relationship
between post-cibal duodenal PG synthesis and duodenal acid 
load was examined (78), patients with duodenal ulcers had 
lower PGI2 values than healthy controls.
2.3.2. Influence of Local Inflammation.
One possible explanation for the obvious discrepancy 
in the results of studies described above is the fact that 
most previous workers have failed to take into account the 
interaction between local inflammation and PGs. The role 
played by PGs in mediating the inflammatory responses was 
described well before the discovery of their activities in
maintaining the mucosal defences. Innumerable
publications have indicated that NSAIDs reduce the 
vasodilatation, oedema and pain of inflammation by 
inhibiting PG synthesis. It was also shown that,
although they did not act directly, PGs enhanced 
enormously the oedema and pain-producing effects of other 
mediators, such as histamine, bradykinin and complement 
component C5a (79-81). In addition, PGs were found to 
play a role in influencing local c.AMP production (82). 
PGE2 and prostacyclin are among the most potent
stimulators of c.AMP generation. A rise in c.AMP was 
associated with a reduction of lymphocyte stimulation, 
cell mediated cytotoxicity, antibody and lymphokine
production, release of lysosomal enzymes and allergic 
release of histamine (82). Although all the major
immuno-inflammatory cell types except lymphocytes are 
capable of generating PGs after an appropriate stimulus, 
in general the macrophages seem to be the major source 
(83,84). Human neutrophils and macrophages produce
mainly PGE2 and TXA2 as a result of stimulation by various 
materials, such as phagocytic stimuli (zymosan, antigen- 
antibody complexes), lymphokines and bacterial endotoxin 
lipopoly-saccharide. The production of PGs by
neutrophils is relatively short lasting, which might 
indicate a somewhat different function, e.g. 
vasodilatation, to that of the PGE release from 
macrophages which occurs over a much longer period. The 
latter would be consistent with the PGE activity in an
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immunoregulatory function. Cultures of macrophages
produce both PGE2 and PGI2 when exposed to an inflammatory 
agent such as zymosan (85).
Schlegel et al. (86) were the first to demonstrate
that patients with gastritis and gastric ulceration had a 
higher rate of PG synthesis than subjects with normal 
mucosa. This was confirmed by subsequent studies (87) 
including one presented in this Thesis (Chapter 11).
It is also interesting to find that, in the presence 
of H. pylori, gastritis does not seem to be associated 
with increased PG production, as shown in Chapter 11.
It has to be emphasized that the above studies
(86,87,Chapter 11) simply confirm the involvement of PGs 
in the inflammatory response. They do not necessarily 
contradict the hypothesis that PG deficiency may be a
factor in the genesis of peptic ulcer. This is because 
PGs could not be measured in the phase that preceded
ulceration.
2.3.3. Tissue Sampling and the Types of Prostaglandin 
Assays.
The fact that tissue trauma stimulates PG synthesis 
has been widely recognized (88). Several workers have 
attempted to minimise the effect of this phenomenon by 
washing the biopsy specimens before incubation and/or the 
use of fresh un-homogenized tissue. Among those who 
washed their biopsies are Wright et al. (65), Konturek et 
al. (64,89), Hillier et al. (77) and the studies included
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in this Thesis. The duration of the washing period is 
not very critical but it should be standardised to all the 
specimens examined in a particular study. Generally
speaking, the longer the washing period the more likely it 
is to remove greater amounts of PGs induced by the initial 
trauma of obtaining the biopsy. In these circumstances 
it is preferable to consider measures of helping the cells 
to stay alive, especially if the washing and incubation 
periods are to continue for many hours. In two of the 
studies included in this Thesis (Chapters 12 and 13) a 
standard culture medium, RPMI 1640 (Gibco) is used. 
Among the workers who used culture media, RPMI 1640 in 
particular, are Sharon et al. (76) and Rachmilewicz et al. 
(90). Two sources of trauma can however be identified in 
their experiments (76,90); the first relates to obtaining 
the biopsies which were not initially washed, and the 
second is due to homogenization which involves the 
breaking up of cells to stimulate further PG synthesis. 
Homogenization was also used by several other authors 
(19,20,65,78,91).
Another basic principle that needs to be considered 
is whether to freeze the biopsies or to keep them fresh 
till the time of PG measurement. Frozen tissue was used 
by some workers (77,92,93), but Bennet et al. (19) used 
both fresh and frozen tissue in the same study. Many 
other authors used fresh biopsies only (65,76,78,87,90). 
Freezing specimens helps to store them till the time 
recruitment is completed, when biopsies from all study
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subjects could be assayed together. Fresh tissue, on the 
other hand, is relatively closer to physiological 
circumstances within the gastric or duodenal mucosa. The 
effect of freezing is clarified in Chapter 6 of this 
Thesis. Frozen specimens produce more PGE2 and PGI2 than 
fresh ones. This could be related to the destruction of 
cell membranes within frozen tissue. The issue could 
become complicated by the inclusion of other procedures 
such as homogenization (76,90) or the addition of 
extrinsic precursors (20,78,87,91) to the PG assay. To 
homogenize a fresh specimen probably removes its relative 
physiological advantage over a frozen one because of the 
trauma involved. Also, the addition of extrinsic
precursors only allows for measurement of the capacity of 
the cyclo-oxygenase enzyme to utilize them; it does not 
necessarily measure PG synthesis from intrinsic precursors 
stored within the cell membranes.
In this Thesis, extrinsic precursors are not added 
when frozen biopsies are studied. Neither is
homogenization used in studies involving fresh tissue.
Previous studies have also differed in the type of PG 
assay used. Bioassays and column chromatography were 
used by some early workers (19,86) while the majority of 
others, including this Thesis, relied on 
radioimmunoassays. Assay insensitivity was previously 
recognized as a potential source of problems in tissue PG 
measurements (94).
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Another area that needs clarification is whether an 
assay is measuring PG concentration or synthesis. Some 
authors (65) spoke of mucosal levels and this is difficult 
to interpret since PGs are not stored. To prove that PG 
synthesis has taken place, it was suggested (95) that 
evidence should be shown that the assay could detect PG 
inhibition by cyclo-oxygenase inhibitors. In this
Thesis, and in addition to unpublished preliminary data, 
evidence is presented showing that PG inhibition takes 
place in response to naproxen (Chapter 10) and
indomethacin (Chapters 12, 13). Also, the assay used can 
detect stimulation of PG synthesis by histamine (Chapter 
13).
In conclusion, there are many problems still 
surrounding PG measurements. Satisfactory interpretation 
of the findings of a given measurement could be
facilitated by adequate description of the procedures
used, standardizing these procedures to all the study
groups, and by describing the tendency of PGs measured to 
rise, fall, or stay unchanged, rather than comparing 
individual tissue concentrations. Physiological values 
of tissue PGs have not been measured yet.
2.4. Prostaglandin Measurement in this Thesis.
The overall process of measuring tissue PGs can be 
divided into the following stages: the washing period,
the incubation period, and the radioimmunoassay. 
Measures to stabilize PGs are observed during all stages.
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The following is a general discussion of these stages, and 
individual variations will be mentioned in the appropriate 
Chapters.
Some studies in this Thesis use frozen specimens 
while others use fresh ones. The implications of this 
issue have been discussed in the previous section, in the 
context of other principles of tissue sampling.
Immediately before biopsies are incubated, they are 
washed in phosphate buffered saline, or in RPMI 1640 if 
tissue culture techniques are to be used subsequently. 
The purpose of the washing period was to minimise 
measurement of PGs induced by trauma. Its duration
varies between studies but it is standardized to all 
specimens within the individual studies.
The washing supernatant is removed and the specimens 
are then incubated in either fresh buffer, or culture 
medium with or without test materials such as H. pylori 
culture filtrate. The supernatants yielded from this 
process are added to an equal volume of methyloximating 
(MOX) agent to stabilize their content of PGs (96). As 
mentioned earlier, a cause of many problems in PG 
measurement has been the low concentrations of PGs in many 
body fluids, together with the instability of PGs with a 
-ketol ring structure (PGE series). Using the oximating 
solution, PGs are reliably and conveniently converted to 
their methyloximes in high yield (greater than 95% for 
room temperature oximation) even in complex biological
matrices such as plasma (96). The exact degree of
conversion is difficult to assess since no radio label is
100% pure, but T.L.C. analysis of the product showed less
than 2% of the radioactivity corresponding to the
unchanged PG. Data from the examination of the two
isomers of PGE2 suggest that in this case it is only the
major methyloxime isomer which is recognized. There are
many advantages of having stable derivatives of PGs for a
radioimmunoassay: the samples are particularly stable
during extended storage and during the assay procedure
itself. The presence of oximating solution (50%) also
inhibits bacterial growth, and increases both the
sensitivity and the specificity of the assay (96,97).
The reagents such as label and standards are also stable,
and the stability of the substrate is important during
1 7 5iodination procedures to prepare labelled compounds.
During the radioimmunoassay, alliquots are assayed in 
duplicate. They all carry code numbers to facilitate 
randomization. Intra-assay variations are 14.8 for PGE2 ,
11.0 for 6-oxo-PGF^ (the stable metabolite of PGI2 ), and
5.0 for TXB2 (the stable metabolite of TXA2 ). Inter­
assay variations are 13.5 - 26% for PGE2 , 13.0% for 6-oxo- 
PGF^ , and 5.6% for TXB2 . Cross-reactions of the anti­
sera are as follows: PGE2 (M0X) anti-serum with E*^ ,
53%; PGE3, 31%; PGB2, 0.2%; 15-oxo-PGE2, 0.25%. 6-
oxo-F^ (M0X) anti-serum with TXB2 , 0.02%; PGE2 > 0.01%; 
PGE^, 0.01%. TXB2 anti-serum with PGD2 , 0.02%; 6-oxo 
E-j^, 0.02%; PGE2 , 0.02%. The sensitivity of the PG assays
(as defined by the amount distinguishable from zero with a 
95% confidence limit) is 2 pg in all assays. Other 
details are as previously described (96,97). Results
are expressed as ng or pg per mg protein or tissue weight. 
Tissue protein is measured by the Lowry method (98). It 
is worth noting that there is a correlation between the 
weight of mucosal biopsies and their protein content (65). 
To express PG values per either parameter will therefore 
make no significant difference to the overall 
interpretation of results.
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CHAPTER 3
3. GASTRIC AND DUODENAL COMPLICATIONS OF
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS.
3.1. INTRODUCTION.
Numerous studies, including some reported in this 
Thesis, have dealt with the issue of gastric and duodenal 
side effects related to the use of non-steroidal anti­
inflammatory drugs. Opinions have, however, varied as to 
whether these agents do increase the frequency of 
complications like perforation, bleeding or death. The 
purpose of this chapter is to assess the evidence for and 
against the involvement of these drugs in causing serious 
side effects and to discuss the possible mechanisms by 
which they affect the gastric and duodenal mucosa.
3.2. DO NON-STEROIDAL ANTI-INFLAMMATORY DRUGS INCREASE
THE RISK OF SERIOUS GASTRIC AND DUODENAL 
COMPLICATIONS? EVIDENCE FOR AND AGAINST.
Non-steroidal anti-inflammatory drugs (NSAIDs) are 
one of the most commonly prescribed group of drugs. In 
1983, it was estimated that sufficient prescriptions were 
written to provide 1.29% of the adult population of the 
United States with NSAIDs, and usage patterns projected 
the continuation of this trend (99). In the United 
Kingdom, the total number of prescriptions for NSAIDs rose 
from 7.6 in 1967 to 22 million in 1985 (100). This rise 
covered individuals of all ages, but the rates of
60
prescription were consistently greater in elderly people; 
it was estimated that every individual over the age of 65 
could on average receive at least one prescription for an 
NSAID in any 1 year (100). It is interesting to notice 
that the Food and Drug Administration (FDA) in the United 
States and the Committee on Safety of Medicines (CSM) in 
Britain receive more reports of adverse effects ascribed 
to the use of NSAIDs than of those thought to have been 
caused by any other form of treatment (101-103). It was 
also suggested that gastrointestinal events were the most 
common side effects of NSAIDs (104). In a study by 
Caruso et al., the overall incidence of endoscopically 
confirmed gastric lesions during treatment with anti­
inflammatory drugs was 31% (105). Despite the importance 
of these observations, a lot of controversy has surrounded 
the evidence for an increased risk of serious 
complications in association with the intake of NSAIDs. 
Several factors have to be considered in this context, but 
the main source of controversy probably relates to the 
methodology involved in the measurement of the above risk.
In the early stages of evaluating the possible 
toxicity of a new NSAID, it is almost always the case that 
an animal model is used. Experiments involving such 
models usually measure the number and size of ulcers or 
erosions induced by the agent in question, often under a 
stressful environment. The dose of the drug tested, per 
animal weight, is very large in most cases. These
experiments might not necessarily reflect the natural
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history of peptic ulcer disease in man, and species
specific responses can be of crucial importance.
Therefore, the capacity of an individual NSAID to cause 
ulceration under these circumstances might be of limited 
relevance to man.
An important source of data on the toxicity of
NSAIDs, which is relied on by the pharmaceutical 
companies, the FDA, and the CSM, comes from the so called 
"Phase Three Trials". These are double-blind, controlled 
trials, usually of relatively brief (three months or less) 
duration. The test drug is compared to a standard drug 
or, less commonly to a placebo. These studies produce 
highly reproducible findings; for example, the proportion 
of subjects with gastric or duodenal side effects after 
taking an individual NSAID does not vary greatly from one 
study to another. The limitations of these studies is 
that they involve relatively small numbers of patients, so 
that rare but serious side effects would be missed. 
Another major problem is that the subjects studied are
select populations, thus excluding many individuals with a 
history of gastro-intestinal problems. More importantly, 
those older than age 65 or 70 years are almost never 
included. This can be considered a serious omission for 
reasons described below.
Another means of assessing drug toxicity involves 
voluntary reporting by clinicians to a regulatory agency, 
such as the CSM, of a reaction thought to have been caused 
by a drug. The voluntary nature of this system may
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result in an under-estimation of the common or expected 
toxicity with a relative over-estimation of the bizarre 
effects. Also, the CSM regularly informs clinicians of 
the introduction of new agents, and requests them to watch 
for, and report any side effects they may cause. For one 
reason or another, there is a tendency to report more on 
the newly introduced agents than on the established ones.
The 1980s saw the publication of several studies that 
attempted to estimate the risk of upper gastrointestinal 
bleeding, perforation, or death from aspirin or non­
aspirin NSAIDs. These studies have often come up with 
conflicting conclusions.
An important study was reported by Coggon and 
colleagues in 1982, in which they retrospectively assessed 
aspirin intake in patients with haematemesis and melaena 
and in controls (106). In order to validate their data 
further, they chose age-and sex-matched community 
controls, and used paracetamol as a positive control. By 
this, Coggon et al. felt that they could then obtain an 
unbiased estimate of ordinary community drug use, and that 
the paracetamol data enabled them to estimate the extent 
to which patients who developed haematemesis and melaena 
might ordinarily be taking analgesics. They assumed that 
paracetamol intake was not associated with upper 
gastrointestinal complications. This study (106) found 
that, compared to community controls, more patients with 
haematemesis and melaena took aspirin, paracetamol and 
other NSAIDs. Coggon et al. estimated that about one-
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third of aspirin intake in patients with bleeding was 
equivalent to that in controls and was by deduction non- 
causal; another one-third by reference to parallel 
increases in paracetamol intake was non-causal but 
consequential upon the presence of the bleeding lesion. 
The remaining one-third was unexplained and likely to be 
causal. Among chronic users of aspirin in the Nottingham 
community, they also estimated that 1 in every 1000 would 
be likely to be admitted with haematemesis and melaena 
each year. This figure is in agreement with that
suggested by data reported in the Boston Collaborative 
Study (107).
In another study, Armstrong and Blower (108) aimed at 
relating NSAID ingestion to all cases of peptic ulceration 
with perforation or bleeding, who either died or underwent 
emergency surgery in the South Cheshire Health District. 
During a three year period, they found that 80% of those 
dying from ulcer complications had received NSAIDs. 
Another investigation aiming at identifying all cases of 
death from peptic ulcer and relating these to use of 
NSAIDs was conducted by Catford and Simpson (109). They 
reported the findings of an enquiry into deaths from 
peptic ulcer in Hampshire between 1981-3. Information 
was sought by questionnaire about all those whose death 
certificates indicated peptic ulceration. During the 
data collection phase, industrial action was undertaken by 
the Registrars of Births and Deaths. This resulted in 
many death notifications being forwarded too late to
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gather complete information. Nevertheless, where
information was available about those dying in hospital, 
approximately 50% had been on NSAIDs. Series of cases, 
suggesting high exposure to NSAIDs amongst patients with 
peptic ulcer disease or its complications, have also been 
reported by Collier and Pain (110), and O'Brien and 
Burnham (111). Caution is advised in interpreting such 
findings because case series might emphasize the unusual, 
patients with one disease could be more susceptible to 
having another, and because patients with an indication 
for NSAID intake might be more prone to gastro-duodenal 
damage due to any cause. More importantly, peptic ulcer 
disease is common in the general population and one should 
be aware of the possibility that a simple coincidence 
might take place between two common events: NSAID intake
(99,100) and peptic ulcer disease.
While the studies described above have strongly
suggested the presence of a high risk of peptic ulcer 
complications in patients on NSAIDs, there are studies 
that have concluded that the risk is either low (112) or 
negligible (113).
Carson et al. (112) studied upper gastro-intestinal
bleeding in approximately 92,000 subjects. Using data
from almost 50,000 subjects prescribed NSAIDs, they found 
a rate of bleeding of 0.33% in the first 30 days compared 
with 0.22% for controls, for a relative risk of 1.5%.
Thus, the risk of upper gastro-intestinal bleeding in the 
first month of NSAID treatment^ according to Carson et al.
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is 50% over the expected rate. In other words, in two- 
thirds of patients with upper G.I. bleeding within a month 
of starting NSAID therapy, the cause is unrelated to NSAID 
intake. It is important to note that Carson et al. 
excluded from their analysis patients with a history of 
upper G.I. bleeding. It would be crucial to look at this 
group of patients to determine the risk of NSAID-induced 
bleeding in them. Moreover, the analysis only included 
bleeding within the first month. Later bleeding and 
"silent" ulcers would have been missed.
In another study, Jick et al. (113) examined the 
frequency of hospital admission for perforated peptic 
ulcer in relation to the use of NSAID at the Group Health 
Cooperative of Puget Sound, Seattle, U.S.A. Their study 
found that 54 people were admitted to hospital with well- 
documented perforated peptic ulcer. Among these cases, 6 
had presented a prescription for an NSAID within 90 days 
before hospital admission, resulting in a crude rate of 6 
hospital admissions per 23.4 million person-days at risk 
(0.26 per million person-days at risk) among NSAID users. 
The crude hospital admission rate among non-users was 48 
per 559 million person-days at risk (0.09 per million 
person-days at risk). Jick et al. concluded that the 
frequency of hospital admission for perforated ulcer was 
not measurably affected by concurrent use of NSAIDs at the 
Group Health Cooperative of Puget Sound. However, as 
pointed out by Jick et al., their crude estimates were 
confounded by age which is strongly positively associated
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with both rate of hospital admission and NSAID use (100). 
Adjusted for age and sex, the rate ratio for NSAID users 
compared with non-users was 1.6 (95% confidence interval 
0.68-37).
The other study that disputed the suggestion of an 
increased risk of ulcer complications in NSAID users was 
reported by Inman and Rawson (114,115) in 1985. They 
assessed the results of more than 50,000 patients treated 
with benoxaprofen, fenbufen, zomepirac, indomethacin or 
piroxicam. It covered a period equivalent to 90,000 
patient years of observation, about half during and half 
after stopping or changing treatment. They estimated 
that the frequency of upper gastro-intestinal bleeding or 
perforation ranged from three to six cases per 1,000 
patient years, only a minority being attributed to NSAIDs 
by the reporting doctor. According to their data, these 
complications occurred with equal frequency after the 
patients stopped or switched NSAIDs and were very rarely 
caused by these drugs. The methodology involved in 
collecting and analysing the data of Inman’s study might 
explain why NSAID use appeared free from ulcer 
complications. Although a large number of subjects were 
included in the study as a whole, the numbers of those 
taking the individual NSAID might not have been big enough 
to detect an increased risk. Also, the study included 
subjects of all ages, and this overlooks the possibility 
that ulcer complications could have been predominant in 
older patients. In addition, only 50% of questionnaires
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sent to general practitioners were returned, and these 
were mailed up to a year after the prescriptions were 
issued initially.
Many of the limitations of the above studies (108-
115) were addressed by a study reported by Somerville et 
al. (116) in 1986. Four hundred and six of 903 patients 
admitted to two Nottingham hospitals with suspected upper 
gastro-intestinal bleeding were diagnosed as having a 
bleeding gastric or duodenal ulcer. Of these, 327 
patients were questioned and the 230 cases aged 60 or over 
were matched with both community and hospital inpatient 
controls. This study found that the use of non-aspirin 
NSAIDs amongst the bleeders increased with age, 
particularly over the age of 60, when at least one-third 
of patients were takers. Bleeders were found to be at 
least twice as likely to be NSAID takers as controls, the 
relative risk being 3.8 and 2.7, compared respectively 
with hospital and community controls. The differences 
between cases and either type of control were highly 
significant.
It is not clear why the elderly should be so 
seriously affected by the adverse effects of NSAIDs (108-
116). Large numbers of prescriptions are written for 
this age group, probably because of the increasing 
incidence of osteoarthritis with age, while those with 
rheumatoid arthritis are on the whole younger. About 
half of the NSAIDs prescribed are for the over 60s (100). 
Not only is the incidence of gastro-intestinal
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complications high in the elderly, but the outcome in 
terms of mortality is much worse, the case fatality rate 
being three times greater in the over 70s in Armstrong and 
Blower’s series (108). In addition to the high rate of 
NSAID prescription (100), there are other factors that 
might help explain the susceptibility of the elderly to 
NSAID related peptic complications. Sonnenberg (117) 
found a significant correlation between geographical 
variations in salt consumption and mortality from gastric 
ulcers. He suggested that dietary intake of salt was a 
risk factor in mortality from gastric ulcer. Sonnenberg 
has also argued for a cohort effect (118), starting at an 
age below 5 years for both gastric and duodenal ulcers. 
This effect implies that important determinants for the 
development of peptic ulcer disease occur very early in 
the life of a cohort and that it is these early 
determinants that are changing with time. It could be 
speculated that subjects born in the early years of the 
20th century were exposed to one or more factors that 
predisposed them to ulcer formation later in their lives. 
This interesting proposition is probably too simple to 
explain all the variations of peptic ulcer disease or its 
complications.
In conclusion, opinions have differed as to whether 
NSAIDs are causally related to serious complications of 
peptic ulcers. Such difference could be due to the
methodology involved in various studies. On balance, the 
evidence for a causal relationship has been more
69
convincing. The importance of even a small rise in the 
relative risk is emphasized by the high rate of 
prescribing NSAIDs, particularly in elderly subjects.
3.3. INTERFERENCE WITH PROSTAGLANDIN SYNTHESIS BY 
NSAIDs.
It is generally agreed that NSAIDs such as 
indomethacin inhibit PG biosynthesis by inhibiting cyclo- 
oxygenase activity, the enzyme which is responsible for 
converting arachidonic acid substrate to PG intermediate 
PGG2 . This is subsequently converted to the endoperoxide 
intermediate PGH2 which by the action of specific PG 
synthetase enzyme is converted to a large number of 
possible PGs or their derivatives (Figure 1). NSAIDs 
are considered not to have any major effects on the 
enzymes involved in the lipoxygenase system, and therefore 
the production of the leukotrienes would only be affected 
by these drugs to the extent that further arachidonic acid 
substrate would be available for leukotriene biosynthesis 
on account of the decreased PG production.
The potencies of various NSAIDs in inhibiting PG 
synthesis have been indicated in previous reports (119). 
Indomethacin, naproxen and meclofenamic acid are powerful 
inhibitors of PG synthesis, phenylbutazone is a moderate 
inhibitor, while salicylic acid, aspirin and benoxaprofen 
are only weak inhibitors. Evidence is presented in this 
Thesis indicating that etodolac does not seem to suppress 
PG synthesis in the gastric or duodenal mucosa of patients
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with rheumatoid arthritis who took the drug for 4 weeks. 
The mechanism by which this agent causes gastric or
duodenal side effects probably involves one or more of the 
non-PG dependent processes discussed below. Other drugs 
act as prodrugs that show activity through their
metabolites: one of these agents is suldinac whose
sulphide metabolite is able to exert a potent inhibiting 
effect on PG synthesis (120).
In addition to their direct effect on the cyclo- 
oxygenase enzyme, NSAIDs can stabilize lysosomes and
inhibit the release of lysosomal enzymes including lipases 
(121). This will interfere with the release of
arachidonic acid from cell membranes (mediated by
phospholipases) and in turn can inhibit the production of 
PGs, especially when high concentrations of NSAIDs are 
present.
A further feature regarding the effect of NSAIDs on
PG production which should be noted is that certain drugs
may show selectivity in terms of which PGs are mainly
affected. Previous observations with sheep vesicular
+9tissue incubated in Cu -containing medium indicated that 
salicylic acid caused a preferential reduction in PGE2 
synthesis relative to PGF2 synthesis (122); the latter in 
fact was stimulated in the presence of Cu+ .^ In
contrast, indomethacin suppressed the production of PGE2 , 
PGI2 and PGF2 to the same extent. This phenomenon of 
selective inhibition might be relevant to the action of 
etodolac. By decreasing rheumatoid disease activity one
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speculates that it suppresses synovial PG production, thus 
displaying a form of tissue selectivity, bearing in mind 
that it does not affect PGs of the stomach or duodenum. 
Alternatively, one could also speculate that etodolac 
selectively suppresses other PG compounds not measured in 
the study described in this Thesis. Assuming this is 
true, it is unlikely to be of great significance because 
PGE2 , PGI2 , and TXA2 are the major PG groups in the human 
gastric and duodenal mucosa.
3.4. OTHER MECHANISMS OF MUCOSAL TOXICITY.
In addition to their capacity to interfere with PG 
synthesis, NSAIDs have several other activities which can 
lead to mucosal damage. These actions should not be 
considered as totally separate from each other. For 
example, the capacity of indomethacin to decrease mucosal 
blood flow (44,123,124) is not necessarily unrelated to 
its inhibitory effect on PG synthesis, which in turn can 
influence blood flow (125). Like indomethacin, aspirin 
was found to decrease mucosal blood flow (124), although 
an earlier report suggested the reverse (126).
Aspirin (127), indomethacin (125) and fenoprofen 
(128) were also found to cause disruption of the gastric 
mucosal barrier in a manner that allows back diffusion of 
hydrogen ion with its damaging consequences. Aspirin and 
indomethacin also increase basal (129) and maximally 
stimulated gastric acid secretion (124,130), which may 
contribute to their unwanted effects on the gastric and
72
duodenal mucosa.
Several studies have suggested that NSAIDs can affect 
the rate of secretion and/or the characteristics of the 
mucus layer in the stomach. Aspirin (131) and
indomethacin (132) were found to inhibit mucus secretion. 
It was also suggested that aspirin could increase pepsin- 
mediated proteolysis of mucus, decrease mucus viscosity 
and increase the permeability of mucus to hydrogen ion 
(133). Indomethacin was also found to inhibit active 
bicarbonate secretion by the gastric mucosa (134).
Another mechanism, that received little attention in 
the past, relates to the possibility that bacteria may 
mediate NSAID toxicity. In the intestine, it was
observed that the ulcerogenic effect of NSAIDs could be 
reduced by antibiotic treatment (135). Germ-free animals 
were also found to be resistant to indomethacin-induced 
intestinal lesions (136). It was postulated that enteric 
bacterial ^-glucuronidase hydrolyses the acylglucuronides 
of NSAIDs released into the intestinal tract from the 
bile, and the free acids then irritate the mucosal surface 
(135). Interest in these important observations has been 
revived by the recent entry into the argument of another 
organism: Helicobacter pylori. It is not clear whether
NSAIDs interact with H. pylori in the gastric mucosa. 
Evidence is presented in this Thesis showing that human 
gastric antral specimens exposed to a mixture of 
indomethacin plus H. pylori culture filtrate have lower 
PGE2 values and histological grades than biopsies
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incubated with indomethacin or the culture filtrate alone. 
The results of this in vitro study suggest that an 
interaction may exist between indomethacin and H. pylori 
culture filtrate. Such interaction appears to be
damaging to the gastric mucosa as judged by the 
histological findings and PGE2 measurements.
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CHAPTER 4
4. HELICOBACTER PYLORI AND PEPTIC ULCER DISEASE.
4.1. INTRODUCTION AND HISTORICAL BACKGROUND.
In 1983, an organism was "rediscovered” by Warren and 
Marshall (137). It was initially called Campylobacter 
pyloridis but the name was later changed to Campylobacter 
pylori and more recently to Helicobacter pylori (H. 
pylori). This organism appears to be ubiquitous and the 
population seems to be continuously exposed to it. The 
possibility that H. pylori might be the cause of peptic 
ulcer disease (138) has generated a lot of interest.
The bacterium has been isolated worldwide, usually 
from the stomach, especially from the antrufn and less 
often from the corpus fundus area (139).
H. pylori is a microaerophilic organism which grows 
best in blood agar in a humid atmosphere. It appears as a
curved, spiral or S-shaped Gram-negative rod, 2.2 - 3 um
long and 0.5 um in diameter in fresh specimens of gastric 
mucus. The organism has a smooth coating and four to 
five flagella projecting from one end. These flagella are 
sheathed and have terminal bulbs (140).
4.2. CLINICAL EVIDENCE OF PATHOGENICITY OF H. PYLORI.
The evidence that H. pylori is a true pathogen has 
been increasing; several observations indicate that the
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organism is not simply a commensal or an opportunist which 
colonizes inflamed gastric mucosa.
First, many centres all over the world have produced 
data confirming the close association between H. pylori 
and the presence of active chronic gastritis and peptic 
ulcer disease (141-143).
Second, some investigators attempted to fulfil KochTs 
postulates by self-inoculation with the organism. 
Postulate three (the organism in pure culture must produce 
the same disease in a susceptible animal) and postulate 
four (the organism should be found in the diseased areas 
produced in the susceptible animal) were fulfilled by 
Marshall. Seven days after ingesting 10^ organisms, he 
developed a mild gastrointestinal illness and, on antral 
biopsy, was found to have acute gastritis. Cultures of 
antral mucosa grew H. pylori (144).
Third, additional evidence may be derived from
observations of sudden hypochlorhydria. An observation 
of hypochlorhydriac gastritis in 17 of 37 volunteers who 
underwent acid secretion studies with a pH electrode that 
had not been sterilized between experiments appeared, in 
retrospect, to have been caused by H. pylori
contamination (145).
Fourth, it was reported that a patient with
Zollinger-Ellison syndrome suddenly became achlorhydric 
after an episode of general malaise and mild fever (146). 
Gastric histology revealed marked active inflammation and,
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in retrospect, evidence of H. pylori infection. This 
patient was re-examined some 10 years later. He still had 
evidence of massive H. pylori infection, together with 
active chronic gastritis (147). The course followed by 
the above patient is consistent with Marshall’s Hypothesis 
(144) which suggests, among other things, that if H. 
pylori is not cleared by natural immune processes, 
patients with persistent gastrointestinal disturbance will 
also develop achlorhydria.
4.3. THE ASSOCIATION BETWEEN H. PYLORI, GASTRITIS AND, 
GASTRIC ULCERS.
After H. pylori was described in chronic gastritis by 
Warren and Marshall (137), data produced by subsequent 
investigators have pointed to a very close, if not causal, 
link between H. pylori and what is now known as Type B 
gastritis (see below). In a recent review of world
literature (148) of H. pylori - associated gastritis, in 
over 1,000 patients, those with gastritis had a 75% 
carriage rate of H. pylori compared with under 10% in 
those without gastritis. Of 54 asymptomatic volunteers 
studied, 11 had both gastritis and H. pylori compared with 
none of the 43 patients without gastritis. H. pylori 
appears to be associated with a specific gastritis that 
predominantly affects the antrum and involves infiltration 
of the epithelium and interstitial tissue with 
neutrophilic polymorphs, lymphocytes, and plasma cells 
(137). A similar histological picture was originally 
called active chronic gastritis by Whitehead in 1972
(149), or Type B gastritis by Strickland and Mackay in 
1973 (150). This is to be distinguished from autoimmune 
gastritis (Type A), the combined form (Type AB), and 
chemical gastritis (Type C). Autoimmune gastritis is 
known to affect mainly gastric body mucosa; it is 
associated with hypochlorhydria, antiparietal cell 
antibodies in the serum, and pernicious anaemia. Type AB 
gastritis was suggested by Glass and Pitchumoni (151) to 
indicate the presence of patchy involvement, of both 
antrum and body, with multifocal atrophy and intestinal 
metaplasia; it is thought to carry an increased risk of 
gastric ulceration and the development of carcinoma. 
Chemical gastritis (Type C) has been recently suggested to 
describe the histological picture induced by enterogastric 
reflux (152) or other chemicals like NSAIDs (153). It 
results from persistent injury to the surface epithelium 
and is characterized by compensatory fovealar hyperplasia 
and a vascular and exudative response evidenced by 
capillary dilatation, congestion and oedema of the lamina 
propria. There is no notable increase in inflammatory 
cells.
There are two further characteristics of Type B 
gastritis that are worth mentioning. The first relates 
to the finding of lymphoid follicles, frequently seen when 
the inflammatory cell infiltrate extends through the full 
thickness of the mucosa, and by separating the glandular 
elements, may give a false impression of atrophy (154).
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These reactive lymphoid follicles are virtually confined 
to H. pylori positive gastritis (155).
The second characteristic relates to the development 
of intestinal metaplasia. This might take the form of 
small intestinal or colonic type mucosa, and probably 
results from persistent chronic inflammation. Its
importance stems from the suggestion that it might 
represent a premalignant condition (156). It has also 
been observed that H. pylori organisms do not adhere to 
intestinal epithelium and this could explain the low 
prevalence of H. pylori in Type A gastritis (157).
As mentioned above, there are numerous studies 
suggesting a strong link between active chronic gastritis 
and H. pylori. Estimates of positivity for the organisms 
in this condition have ranged from 70% (158) to more than 
90% (159,160). Similarly, previous studies have shown 
that the prevalence of H. pylori in gastric ulceration has 
generally varied between 63% (142) and 77% (141). In 
some studies, the prevalence was as high as 86% (161) and 
98% (162). Many gastroenterologists and histo-
pathologists believe that there is a strong link between 
gastritis and gastric ulceration (150,163-165). It is also 
believed that gastritis is the fundamental change upon 
which other damaging factors act to induce ulceration. 
Gastritis in this context does not need to be associated 
with H. pylori in all cases. This has been illustrated 
by the works of O'Connor et al. (166), who studied 
biopsies from 54 patients with chronic benign gastric
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ulcer. They found 72% of the patients to be positive 
for H. pylori. Eight of the 15 patients who were
negative, had histological evidence of chemical gastritis. 
In other words, the gastritis found in association with 
benign gastric ulcers may arise from different 
aetiologies, unlike the antral gastritis associated with 
duodenal ulcers; the latter tends to be the specific type 
associated with H. pylori. This can probably explain the 
apparent difference in the prevalence of H. pylori in 
gastric as opposed to duodenal ulcers, being commoner in 
the latter entity (see below).
4.4. H. PYLORI AND DUODENAL ULCERATION.
Several studies have suggested the presence of a very 
close association between H. pylori and duodenal 
ulceration (139,140,162,166). The prevalence ranged 
between 80-100%. H. pylori was identified largely by 
studying biopsy specimens taken from the gastric antrum 
and/or body. An explanation is therefore needed as to 
how duodenal ulceration could be related to an organism 
that colonizes the gastric mucosa.
Gastric metaplasia, the presence of gastric 
epithelium in the duodenum, is found in up to 64% of 
normal individuals (167) and in up to 100% of cases with 
duodenal ulceration or inflammation (168,169). H. pylori 
was also found in the duodenum (170) only in patients with 
both active duodenitis and gastric metaplasia. Wyatt et 
al. (170) found that only patients with a low fasting
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gastric juice pH had gastric metaplasia. It was
suggested that such metaplastic change could be protective 
against acid (169). The ability of the gastric
epithelium within the duodenum to protect against acid 
might become undermined when it is infected with H. pylori
(170). Acid with or without other damaging or
predisposing factors might therefore lead to duodenal 
inflammation and ulceration (170). It should be
emphasized that this sequence of events remains purely 
speculative. A definite aetiological link between H. 
pylori and duodenal ulceration has yet to be established.
4.5. H. PYLORI AND NON-ULCER DYSPEPSIA.
The possible association between non-ulcer dyspepsia 
(N.U.D.) and H. pylori was first suggested by Marshall et 
al. in 1985 (139). Such association does not seem to be 
as strong as that between H. pylori and gastric or 
duodenal ulcers. In this Thesis, H. pylori is found in 
10 out of 26 (38%) of subjects identified as having N.U.D. 
This is slightly lower than that found in a previous study
(171), which identified the organisms in 45% of subjects. 
N.U.D. is defined in this Thesis as having upper abdominal 
complaints such as pain, nausea, vomiting and heartburn 
for a minimum of a month, normal endoscopic findings or 
minor mucosal erythema, normal upper abdominal ultrasound 
scan and without the intake of antibiotics within a month, 
or ulcer healing drugs within a week of endoscopy. The 
identification of this type of dyspepsia might have some 
therapeutic significance. A recent study (172) has found
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that short term De-Nol therapy improved N.U.D.-associated 
gastritis and symptoms, in addition to eradicating H. 
pylori in 83% of patients infected with the organisms.
4.6. MECHANISMS OF INTERACTION BETWEEN H. PYLORI AND 
THE GASTRIC MUCOSA.
The strong association between H. pylori and peptic 
disease has led many workers to explore the possibility 
that these organisms have the potential to cause direct 
damage, or at least to predispose to it. The complexity 
of this issue has also led some investigators to put 
forward their own hypotheses as to how H. pylori interacts 
with the gastric mucosa.
It was postulated (144) that H. pylori causes an 
acute antral gastritis that may resolve or persist as 
chronic gastritis with hypochlorhydria lasting for up to 
12 months. As immunity develops, the inflammation
regresses and acid secretion returns to normal. During 
this, an imbalance may occur between mucosal resistance 
and acid secretion which theoretically may lead to the 
development of a peptic ulcer.
Although H. pylori seems able to establish itself in 
subjects with normal acid secretion in certain situations 
(173,174), its acquisition by ingestion in the 
experimental state may require transient acid suppression 
(144,175,176). It was not possible to identify any 
consistent relationship between H. pylori and acid 
secretion or serum gastrin (177). Recently, Levi and
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colleagues (178) claimed that subjects infected with H. 
pylori had higher serum gastrin levels than non-infected 
individuals. They postulated that hypergastrinaemia in 
these circumstances could lead to hyperacidity and, 
possibly, ulceration.
Since H. pylori possesses high levels of urease 
activity it was thought that such property caused hydrogen 
ion back-diffusion in the gastric epithelium and that this 
was a predisposing factor in gastric ulcer formation
(179). It was also proposed that a function of the urease 
may be to create an insulating neutral-to-alkaline blanket 
around the organism to protect it from the lethal effects 
of gastric acid (159). Subsequent studies have also 
suggested that the very high urease activity is likely to 
be important in colonization of the host, and that
protection from acid is unlikely to be a primary role, as 
the neutral habitat of H. pylori-related organism Stl is 
the non-acid-secreting tissue of the small intestine
(180). In addition, the fact that H. pylori resides deep 
in the gastric mucus layer does not necessarily imply that 
the organisms are trying to avoid the effects of acid.
Sarosiek et al. (181) have recently shown that incubation 
of H. pylori filtrate with gastric mucus led to a gradual 
loss in mucus viscosity. This had a detrimental effect 
on the ability of mucus to retard the diffusion of 
hydrogen ions. They suggested that the degenerative
changes produced in gastric mucus gel by H. pylori may be
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a contributing factor in the pathogenesis of gastritis and 
peptic ulcer.
When opsonic activity of human serum against H.
pylori was assessed, it was found that opsonisation 
depended on the alternative pathway of complement
activation and not on antibody (182). These findings
suggested that antibody played no role in protection
against H. pylori, and that the presence of antibody in
patients sera was mainly of diagnostic value.
The nature and significance of the interaction that 
may exist between mucosal prostaglandins and H. pylori 
have not been fully clear. The importance of this area of 
research stems from the possibility that PGs and H. pylori 
might exert contrasting effects on mucosal defences. 
This issue was first addressed by work included in this 
Thesis (183-185, Chapter 11). Mucosal synthesis of PGE2 , 
PGI2 , and TXA2 was measured in subjects with gastric 
ulcers and non-ulcer dyspepsia. PGE2 an(^  were
higher in patients with severe gastritis regardless of the 
presence of H. pylori. PG values in patients infected 
with the organisms were comparable to those in subjects 
without H. pylori despite the presence of a higher 
proportion of cases of severe gastritis in the infected 
group. This encouraged speculations about the
possibility of at least a partial defect in PG synthesis 
in the presence of H. pylori (183). Goren et al. (186) 
later suggested that patients with H. pylori had low 
values of 6-keto-PGF^ . The significance of such finding
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is not clear, given the fact that PGE2, the major mucosal 
PG compound, was not suppressed to a significant degree
(187).
Another important aspect of H. pylori interaction 
with the gastric mucosa is the possibility that the 
organisms might have cytotoxic activity. Leunk et al.
(188) suggested that H. pylori culture filtrate contained 
a factor that caused cytopathic (cytotoxic) changes in 
Vero (mammalian) cell lines. Cave and Vargas (189) have 
recently shown that a protein isolated from H. pylori 
culture filtrate could inhibit acid secretion by rabbit 
parietal cells. Studies included in this Thesis (Chapter 
12) show that H. pylori culture filtrate does not affect 
the viability of the human gastric mucosa in vitro or its 
PGE2 production after 48 hours of incubation. When
combined with indomethacin, it reduces both PGE2 and 
mucosal histological scores to a greater extent than 
indomethacin or the filtrate applied separately. This 
implies that an interaction may exist between H. pylori 
culture filtrate and indomethacin capable of causing 
damaging effects to the gastric mucosa in vitro. A 
similar trend is noted when H. pylori protein was applied 
in combination with indomethacin (Chapter 13). This
Thesis also shows that H. pylori protein is capable of 
suppressing cyclic AMP production by the human fundic 
mucosa. It also intensifies the inhibitory effect of 
indomethacin and prevents the stimulatory effect of 
histamine on both PGE2 and c.AMP production. Given the
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central role played by c.AMP in mediating various 
physiological activities, these findings suggest that H. 
pylori protein has the potential to influence at least 
some functional aspects of the human gastric fundic 
mucosa.
4.7. SOME METHODOLOGICAL CONSIDERATIONS IN H. PYLORI 
RESEARCH.
4.7.1. Identification of H. pylori.
The methods of identifying H. pylori can be divided 
into those requiring gastric biopsies and those that do 
not. Several approaches have been proposed to identify 
the organisms in gastric biopsy specimens. H. pylori can 
be cultured in fresh specimens (159) or identified by 
histological examination after being stained with a 
modified Giemsa (190). The observation that H. pylori 
produces high urease activity was utilized in devising new 
tests for its diagnosis. When biopsy specimens are placed 
in Christensen’s medium colour changes are observed 
indicating the presence of H. pylori (191). A result can 
be obtained within an hour, but recent modification of the 
technique makes it possible to get a result after one 
minute (192). Another immediate technique involves the 
use of monoclonal antibodies and immunofluorescence, 
giving results within an hour (193).
Tests that do not require gastric biopsies include 
breath tests and serum antibodies. Two breath tests were 
described: the -^carbon (194), and the cheaper -^carbon
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breath test (195). In these tests, carbon-labelled urea 
is given orally. The urea is metabolised and an isotope 
hydrogen will be detected in the breath if H. pylori is 
present. Antibodies to H. pylori can also be detected in 
the blood of infected subjects by either enzyme-linked 
immunosorbent assay (ELISA)(196), or by complement 
fixation (182). It has to be emphasised, however, that 
the titre of these antibodies does not correlate with the 
severity of the gastritis and that their presence is 
valuable only as a diagnostic tool (182).
4.7.2. Methods of Identifying H. pylori in this Thesis.
Two tests are used to detect the presence of H. 
pylori in this Thesis, both requiring gastric biopsies. 
Specimens are assessed by both histology and bacteriology. 
Such an approach takes advantage of the fact that study 
subjects had to be endoscoped in order to define the 
precise nature of their peptic disease. In addition, the 
histological assessment provides the opportunity to define 
the type and the severity of gastritis, and to exclude 
malignancy in patients with dyspepsia in general and in 
those with gastric ulcers in particular. The presence of 
malignancy would exclude patients from entering into any 
of the studies described in this Thesis, for 
understandable reasons. The numbers and the sites of 
gastric biopsies assessed for H. pylori will be indicated 
in the appropriate chapters.
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4.7.3. Culture of Gastric Biopsies:
Culture techniques are modified from those described 
by Marshall et al.(139). Tissue is processed within
three hours of endoscopy. Specimens are macerated in a 5 
ml glass Potter tube with a PTFE tipped piston (McQuilken, 
Glasgow, UK), with a small amount of 0.9% saline. The 
resulting suspension is then plated onto Columbia agar 
base with 7% horse blood (Oxoid Ltd, Basingstoke. UK), 
heated blood agar (Oxoid Ltd), and Skirrow's Campylobacter 
selective medium containing vancomycin 10 mg/1,
trimethoprim 5 mg/1 and polymyxin B 2500 iu/1 (Oxoid Ltd). 
All strains isolated grow on all three media. Incubation 
is performed in sealed culture jars (Don Whitley 
Scientific Ltd, Shipley, UK), with catalysts and 
'Campypak* gas generators (BBL, Cockeysville, USA) to 
provide humid microaerophilic conditions. At 37°C, H. 
pylori appears as small translucent colonies approximately 
one millimetre in diameter at between 48 and 72 hours. 
Identification of H. pylori is confirmed by its 
characteristic appearance on Gram's stain, and positivity 
for oxidase and urease production (A S Rosco, Taastrup, 
Denmark).
4.7.4. Histopathology:
Specimens are fixed in formalin buffered saline, 
embedded in paraffin wax and 5 um sections prepared for 
light microscopy in the usual fashion. Sections are 
stained with Haematoxylin and Eosin, or Cresyl Violet
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(197) The latter makes H. pylori more obvious on gastric 
sections.
Sections are assessed by light microscopy in the 
usual way for the features of chronic gastritis as graded 
by Whitehead et al.(149). Particular attention is paid 
to the presence or absence of Helicobacter-like organisms 
and the activity of the gastritis as indicated by the 
intensity of the polymorphonuclear leucocyte infiltrate in 
the epithelium and in the lamina propria (198).
4.7.5. Collection and Concentration of H. pylori Culture 
Filtrate:
Columbia blood agar containing a heavy growth of H. 
pylori is inoculated into 20 ml Brain Heart Infusion Broth 
(BHI); 0.5 - 1 ml of this is inoculated onto sloppy agar 
plates, and spread by gentle rolling. The plates are 
incubated at 37°C in a glass jar along with platinum 
catalyst and a BBL Campypak to provide a micro-aerophilic 
environment for growth. The jar is left for 4 days, as 
this was found from preliminary experiments to be the 
optimum time for active filtrate production. The plates 
are later frozen at -20°C for 3 days to kill the bacteria. 
After this they are thawed at room temperature (20°C) for 
6 hours. Fluid is then pipetted off and the remaining 
agar spun at 2000 rpm/10 minutes to remove any further 
fluid. This fluid is driven through 0.4 um and then 0.2 
um filters to remove all dead bacteria and agar. The 
resultant liquid is concentrated by transferring it to
dialysis tubing (Sigma) capable of retaining molecules of 
high molecular weight (above 12,000 kd). The tubing is 
sealed, covered entirely by laying in a bed of 
polyethylene glycol and left for 5^  hours. The
concentrated culture filtrate was found to have cytopathic 
activity against Vero cells, in line with previous
findings (188). For determination of the titre of 
cytopathic activity, doubling dilutions of the test
samples are made in tissue culture medium and added to 
wells with cultured Vero cells. The titre is 1:32, i.e. 
32 units of H. pylori filtrate/ml; this is estimated to be 
derived from 5 x 10^ organisms.
4.7.6. Isolation of H. pylori Protein:
The culture filtrate described above is purified 
using G200 Sephadex Column (Pharmacia). Protein
fractions are separated by their size as they flow through 
the column. They are collected overnight at an optical 
density of 280 nm. Two clear peaks of absorbance occur 
(Figure 2); the small peak which appears first, and the 
second much larger peak, which tends to be brownish in 
colour, probably because of serum proteins coming off the 
column at the same time. The fractions corresponding to 
the peaks are taken and concentrated again in polyethylene 
glycol. The small peak protein (H. pylori protein) is 
collected and divided into 100 ul alliquots. These are 
kept frozen at -20°C. To determine the titre of cytopathic 
activity of this protein, doubling dilutions of the test
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Fig. 2. Isolation of H. pylori protein (A) at an 
optical density of 280 mm, with its range 
of cytotoxicity. (B) .represents serum 
proteins which are also present in the 
control fluid.
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samples are made in tissue culture medium and added to 
wells with cultured Vero cells. The titre is 1:16, i.e., 
16 units of H. pylori protein/1 ml; this is estimated to 
be derived from 5 x 10^ H. pylori organisms
4.7.7. H. pylori Culture Control Fluid:
The purpose of using this fluid is to correct for the 
possibility that the effect of H. pylori culture filtrate 
or protein might be due to one of the materials used 
during its preparation. The control fluid is prepared in 
the same way as the culture filtrate or protein, but
without the addition of bacteria. Un-inoculated sloppy 
agar plates are frozen, later thawed, and the resulting 
fluid collected. This is concentrated as described
above. When the control fluid goes through the G200 
column, only one large peak is obtained. This was found 
to have no cytopathic effect against Vero cells.
4.7.8. Gastric Tissue Culture Medium:
The following medium is used in this Thesis when
V
gastric biopsies are incubated with H. pylori culture
filtrate or protein.
RPMI 1640 (Gibco) is strengthened with 50 m molar 
HEPES/1 to act as an extra buffer, 292 mg/1 glutamine 
and 10 ml of 100 m molar/1 pyruvate as precursors for 
anaerobic metabolism. Also, penicillin 50 u/ml,
streptomycin 50 ug/ml, gentamicin 50 ug/ml and 
amphotericin B 1 ug/ml are added in order to inhibit 
bacterial and fungal growth. Leupeptin (Sigma) is used to
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prevent tissue digestion by pepsin or trypsin. In
addition, isobutyl methylxanthine 1 mmol/1 is added in 
order to stabilise c.AMP generated during incubation.
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CHAPTER 5
5. AIMS OF THESIS.
This Thesis aims at investigating the changes in 
gastric and/or duodenal mucosal PG synthesis in a variety 
of conditions related to the pathogenesis of peptic ulcer 
disease.
Some methodological aspects of PG assays are examined 
in Chapter 6. A basic question in PG measurement is 
whether to process tissues fresh or frozen. Chapter 6 
aims at clarifying the effects of freezing gastric and 
duodenal biopsies on their ultrastructure and capacity to 
synthesis PGs.
Gastric prostaglandin synthesis was previously found 
to increase in response to the intake of individual 
essential fatty acids such as arachidonic and linoleic 
acids. Chapter 7 aims at studying the effects of these 
fatty acids on PG production when given as parts of 
naturally occurring oils such as fish oil, evening 
primrose oil and olive oil. The basic fatty acid
constituents of these oils are also analysed, using gas- 
liquid-chromatography. This is because the oils studied 
might contain other fatty acids that could inhibit the 
cyclo-oxygenase pathway.
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Previous workers studying PG synthesis in the 
presence of duodenal ulceration have come up with 
different conclusions. The aim of Chapter 8 is to
measure duodenal mucosal PG production in patients with 
duodenal ulcers. This might help verify the presence or 
absence of deficient PG production in these cases, which 
in turn might have therapeutic implications.
Established NSAIDs, such as indomethacin, were 
previously found to inhibit PG synthesis in the gastric 
mucosa. When these agents were studied, they were often 
given to laboratory animals or to healthy humans, in short 
courses or as one large single dose. There have been 
indications that NSAIDs with potent anti-arthritic 
activity resulted in maximal peptic damage. Section 3 
aims at investigating the gastric and duodenal mucosal 
side effects of two NSAIDs: naproxen, with established
anti-arthritic activity, and etodolac, the first 
representative of a new class of NSAIDs, the pyrano- 
carboxylic acids. Mucosal PG synthesis is measured at 
base-line, and four weeks after naproxen and etodolac are 
taken in therapeutic doses by patients with active 
rheumatoid arthritis. Such design is thought to overcome 
many of the problems encountered by previous studies.
While PGs are recognized for their favourable effects 
on the gastric mucosa, H. pylori has been linked to the 
development of peptic damage. It is not known whether an 
interaction exists between H. pylori and mucosal PGs. 
The aim of Chapter 11 is to measure PG synthesis in the
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presence of H. pylori in patients with gastric ulcers and 
non-ulcer dyspepsia. While acknowledging the importance 
of including patients with duodenal ulcers in a similar 
study, it is worth noting that PG measurements in these 
cases is likely to be complicated by two factors: the
rarity of duodenal ulcer patients who do not harbour H. 
pylori, and the presence of gastric epithelium in the 
duodenal mucosa, known as gastric metaplasia.
The possibility that H. pylori produces a cytotoxic 
factor is investigated in this Thesis. Chapter 12 aims at 
studying the effect of H. pylori culture filtrate on the 
human gastric mucosa. It also investigates the possible 
interaction between H. pylori culture filtrate and another 
mucosal damaging agent, indomethacin, in vitro. Mucosal 
histological scores and PGE2 production are used to 
quantify the response of gastric tissue to these agents.
Although H. pylori has been linked to the development 
of peptic ulcer disease, its effect on the function of the 
gastric mucosa is not fully understood. A protein
isolated from H. pylori culture filtrate has been shown to 
inhibit gastric acid secretion by rabbit parietal cells. 
Chapter 13 aims at investigating the effect of H. pylori 
protein on the synthesis of human gastric mucosal cyclic 
AMP, which acts as a second messenger for a variety of 
gastric functions including acid secretion. PGE2
synthesis is also measured in Chapter 13 because PGs are 
known to interact with c.AMP.
SECTION 2
MUCOSAL PROSTAGLANDIN SYNTHESIS IN 
RESPONSE TO TISSUE SAMPLING, DIET, 
AND DUODENAL ULCERATION.
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SECTION 2. MUCOSAL PROSTAGLANDIN SYNTHESIS IN 
RESPONSE TO TISSUE SAMPLING, DIET,
AND DUODENAL ULCERATION.
INTRODUCTION.
This section deals with three basic issues related to 
PG measurement and metabolism. Chapter 6 investigates 
the consequences of freezing mucosal specimens, as far as 
their ultrastructure and capacity to synthesize PGs are 
concerned. Chapter 7 measures the effect on gastric 
tissue PGE2 and gastric histology of diets containing 3 
naturally occurring oils: fish oil, evening primrose oil
and olive oil. The composition of these oils is also 
analysed, looking for fatty acids that might inhibit PG 
synthesis. Chapter 8 measures duodenal mucosal PGs in 
patients with duodenal ulceration, in order to verify the 
presence or absence of deficient PG production in these 
patients.
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CHAPTER 6.
6. EFFECTS OF FREEZING GASTRO-DUODENAL BIOPSIES
ON THEIR ULTRASTRUCTURE AND CAPACITY TO 
SYNTHESIS PROSTAGLANDINS.
6.1. SUMMARY.
The effect of freezing endoscopic gastric and 
duodenal biopsies prior to prostaglandin (PG) assays on 
their ultrastructure and PG synthesis was studied in 6 
subjects. Frozen samples produced more PGI2 and PGE2 
than fresh ones in gastric and duodenal tissue. Freezing 
also resulted in disintegration of the cell membranes, 
considered as the probable sources of PG precursors, in 
all cells within the individual biopsies. These findings 
indicate that freezing gastric and duodenal biopsies 
before PG measurements results in extensive tissue 
homogenization, which in turn increases PG generation.
6.2. INTRODUCTION.
Gastric and duodenal PG measurements have been beset 
with technical pitfalls and further work in this area has 
been recommended (199). The differences in the quantity 
and type of PGs measured may be partly explained by the 
differences in the types of assays used (19,65,86). The 
effect of various ways of dealing with tissue samples 
prior to carrying out the PG assay is likely to be of 
importance though this is still not clear. For instance, 
duodenal mucosal PGI2 in duodenal ulcer patients was found
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to be normal in a study using fresh specimens (76) and 
deficient by another using frozen biopsies (77). The aim 
of this double-blind study is to investigate the effect of 
freezing gastric and duodenal biopsies on their capacity 
to synthesise PGE2 and PGI2 . Ultrastructural assessments 
are also performed to look for changes that might explain 
the potential of frozen tissue to synthesise PGs.
6.3. SUBJECTS AND METHODS.
Six subjects (5 females and 1 male) aged 32-45 years, 
were included after ensuring that they took no
medications, had normal upper gastrointestinal endoscopy, 
and no histological evidence of gastritis or duodenitis. 
They were all non-smokers. Their blood tests showed 
normal hepatic and renal function, normal haemoglobin and 
normal platelet and blood cell counts. There was no
suggestion of bleeding tendencies. Informed consents
were obtained and the study was approved by the local 
Ethical Committee.
7.5 - 15 mg Diazemuls (diazepam) was given intra­
venously prior to endoscopy. Two pairs of biopsies were 
taken from the gastric antrum and two pairs from the first 
part of the duodenum of each subject. One pair was sent 
for electronmicroscopy and the other for PG synthesis. 
Each pair consisted of one fresh biopsy and one frozen 
biopsy taken within 1 cm of each other. The biopsies
were assigned to either fresh or frozen groups at random.
They were kept for 30 minutes in liquid nitrogen (-190°C,
100
frozen biopsies) or ice (0 - 4°C, fresh biopsies) after 
which they were processed for PG measurement.
PG synthesis was checked after washing the individual 
biopsies in 0.5 ml of phosphate buffered saline for 30 
minutes at 20°C to minimize measurements of compounds 
induced by trauma. The supernatant was discarded and 0.5 
ml of fresh phosphate buffer was added at each of the 
following stages of incubation: at 20°C for 30 minutes,
and at 37°C for 5, 15 and 30 minutes respectively. After 
each stage the supernatant was removed and added to an 
equal volume of methyloximation agent (96), prior to 
radioimmunoassay. The same radioimmunoassay was carried 
out on the methyloximated supernatants of both fresh and 
frozen samples. Protein estimation was made using the
Lowry method (98). The results are expressed in ng/mg 
protein. PGI2 was measured as its stable metabolite (6- 
oxo-PGF-j^  ). All specimens were assayed in duplicate. 
Details of the radioimmuno-assay are as described in 
Chapter 2.
Preliminary studies showed that the mean (SD) initial 
wet weights of unwashed pairs of fresh and frozen biopsies 
(5 - 1.6 mg) dropped only in insignificant amounts over 5 
half hourly consecutive periods of incubation, the first 
of which being equivalent to a washing period. There 
were no significant differences in the changes in weight 
between fresh and frozen specimens.
On arrival at the electronmicroscopy laboratory, the
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biopsies were diced into blocks approximately 1 mm^. 
Five blocks per biopsy were processed for electron- 
microscopy. Light microscopy on 2u thick sections was 
then used to identify areas for ultrastructural 
examination. 50 nm thick sections were then cut to cover 
a 3 mm diameter grid. All biopsies were presented at 
random with no differentiation between fresh and frozen 
specimens.
Statistical analysis included the Wilcoxon’s signed 
ranks test.
6.4. RESULTS.
As seen in Figures 3-6, greater amounts of PG were 
produced by biopsies processed after having been frozen 
prior to incubation.
The electronmicroscopic features of two pairs of 
gastric and duodenal biopsies are shown in Figures 7-10.
The damage caused by freezing involved all the cells 
inspected; it was superadded to the effect of other 
sources of trauma such as that of obtaining the biopsies. 
Since the procedures employed in taking the biopsies, 
fixing and processing the tissues were standard 
throughout, it was not considered necessary to conduct any 
statistical analysis on cells; damage by freezing was 
obviously confined to frozen biopsies only (changes seen 
in 100% frozen cells against 0% in fresh cells).
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Figure 7. Fresh gastric biopsy (xl4160); Healthy looking cells 
with well defined nucleus, cytoplasmic organelles and cell membranes
Figure 8. Frozen gastric biopsy (x8640); Shrunken cytoplasm 
and nuclei, and poorly defined cell membranes
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V
Figure 9. Fresh duodenal biopsy (xl8,000); Good cellular preservation 
with junctional comDlexes and microvilli^surrounding the lumen
Figure 10. Frozen duodenal biopsy (xl8,000); Poor definition of 
junctional membranes with ice crystal formation within the cytoplasm
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6.5. DISCUSSION.
The ultrastructural changes seen in the frozen 
specimens are consistent with those described elsewhere 
(200). The effect of freezing on cell functions is not 
new, and cryopreservatives were suggested about 40 years 
ago when Polge, Smith and Parkes (201) showed that 
glycerol afforded considerable protection to spermatozoa 
during freezing and thawing. It was later shown that 
freezing can result in the loosening of acrosomal 
membranes of the spermatozoa because of "thermal shock" 
and ice crystal formation within the cytoplasm (202). 
These changes are thought to take place within minutes of 
freezing, hence the term "thermal shock" (202). The 
results of this study are in agreement with these findings 
despite the fact that gastro-duodenal cell membranes are 
thinner and, theoretically, more flexible. However, while 
other cellular functions might be adversely affected by 
freezing PG synthesis appears to be enhanced; this is 
probably due to accumulation of larger amounts of 
arachidonic acid precursors derived from the phospholipids 
of the damaged cell membranes, though this study did not 
measure such precursors.
Where homogenization of tissue prior to testing for 
PG synthesis is to be considered, freezing seems to offer 
a more effective and convenient option, as it can result 
in rupture of 100% cells. This is more extensive than 
using a Dounce (manual homogenizer, 67% cytolysis) and as 
effective as Potter's motorized homogenizer which produces
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95% cytolysis (91,203).
Age, sex, smoking and medications can probably 
influence PG synthesis. Correction for these factors was 
made by studying paired specimens. Other sources of 
variation in reported PG measurements also include the 
type of assay used (19,65,86), and, as shown by the 
results, whether the tissues are frozen or not prior to 
incubation.
In this study the tissues were washed for 30 minutes 
prior to incubation in order to remove PGs synthesised in 
response to the initial trauma of obtaining the biopsy, or 
at least to minimize their measurements; I agree with 
other workers (77) that a shorter period, e.g. 5-15 
minutes, could still be helpful as long as the timing is 
standardized for all specimens studied within the same 
experiment. Also, the incubation period was divided 
into the above stages simply to assess the rate of PG 
synthesis; such division is not essential in other 
circumstances, and one or two stages can be adequate. 
There are no general guide-lines as to whether specimens 
should be processed fresh or after freezing them in the 
context of measurement of endogenous PG synthesis. As 
mentioned in Chapter 2, freezing can be used to facilitate 
storage of specimens till all study subjects have been 
recruited and the study completed. Specimens can then be 
processed together and this helps eliminate the influence 
of many environmental and operator-dependent factors. 
Freezing specimens and the subsequent rise in their PG
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synthesis should not influence the overall interpretation 
of results provided that all specimens assessed in a 
particular study are kept frozen prior to PG measurement. 
Fresh tissue can be used when it is of crucial importance 
to keep as many cells as possible alive during incubation, 
as in Chapters 12 and 13. To homogenize fresh tissue 
(19,20,65,78,91) probably removes its relative advantage 
over frozen tissue because of the damage caused by 
homogenization. If fresh unhomogenized tissue is to be 
used, two issues have to be considered: keeping the
specimens viable during incubation, and stabilizing PG 
compounds till all specimens have been obtained and the 
study completed.
In conclusion, freezing gastric and duodenal 
specimens increases their capacity to produce PGs. This 
is probably due to the breakdown of cell membranes. 
These results emphasize the importance of standardizing 
tissue sampling to all specimens used in a particular 
study. In other words, biopsies can be used fresh or 
after freezing, provided that either procedure is 
standardized to all specimens or study groups.
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CHAPTER 7.
7. THE EFFECT OF DIETS CONTAINING FISH OIL,
EVENING PRIMROSE OIL AND OLIVE OIL ON PROSTAGLANDIN 
e2 SYNTHESIS AND HISTOLOGY OF RAT STOMACH.
7.1. SUMMARY.
Arachidonic and linoleic acids were previously shown 
to have protective effects on the gastric mucosa by 
inducing prostaglandin (PG) synthesis. The natural
sources of these acids like fish, evening primrose and 
olive oils might however contain components capable of 
blocking PG synthesis.
To investigate the effects of these oils on gastric 
PGE2 and the mucosal thickness, 4 groups of rats were fed 
on fat-free diet, 7% fish oil, 7% evening primrose oil 
(E.P.O.) and 7% olive oil diets. Compared to a median 
PGE2 of 2 ng/mg protein in the control group, the median 
PGE2 in rats fed on fish oil was 9 (p<0.01), E.P.O. 50 
(p<0.01) and olive oil 31 ng/mg protein (p<0.001). No 
significant differences were noted in the mucosal heights 
of the 4 groups.
These results suggest that diets containing any of 
these oils can increase gastric PGE2 synthesis. Such 
diets may be potentially useful in the prevention of 
peptic ulcers, given the known protective effects of PGE2.
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7.2. INTRODUCTION.
Polyunsaturated fatty acids like arachidonic and 
linoleic acids, when given to experimental animals, result 
in increases in PG concentrations in gastric juice (59,60) 
which in turn have trophic effects on the gastric mucosa 
(38) and can prevent experimental mucosal injury (60).
It is not clear whether gastric PG production can 
still be increased by these acids when taken as part of 
naturally occurring oils that also contain other fatty 
acids like eicosapentaenoic acid and docosahexaenoic acid; 
these competitively inhibit the utilization of arachidonic 
acid and its precursors by cyclo-oxygenase (12,61,62). 
The aim of this study was to assess the effect on gastric 
tissue PGE2 and the mucosal thickness of diets containing 
fish oil, EPO, and olive oil, as this might have some 
clinical and nutritional implications. The basic fatty 
acid composition of each oil was also determined. The 
choice of these oils was largely influenced by the recent 
interest in the apparently useful roles of fish oil and 
EPO in various systemic diseases (204-210). Little is 
known about the value of these oils and the more widely 
used olive oil in peptic ulcer disease. They are,
however, known to contain one or more of the fatty acids 
mentioned above.
7.3. METHODS.
Four-week old male Lewis rats were used. They 
weighed 100-120 g, and were kept in cages with 12 hour
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light and 12 hour dark cycles. They were allowed free 
access to water and only one kind of diet to which they 
were randomly allocated.
Diets were prepared by Special Diets Services 
Limited, Witham, Essex, CM8 3AD, England. Five hundred 
grams of fat free diet were mixed with 40 ml of each of
the following oils separately: cod liver oil (density of
0.93 g/ml), EPO (0.926 g/ml) and Spanish olive oil (0.916 
g/ml). The oil component of each diet was therefore 
equivalent to 7%. Animals were randomly divided into
four groups according to the type of diet they would 
receive: fat-free diet (n=7, control group), 7% fish oil
diet (n=7), 7% EPO (n=10) and 7% olive oil diet (n=13). 
Diets were renewed and consumed within 2-5 days of
preparation.
After 6 weeks of taking these diets the animals were 
sacrificed in ether. Each stomach was removed, opened 
along the greater curve and its contents washed off under 
a stream of cold water. Full thickness biopsies (5-10 mg) 
were taken from the antral region, immediately frozen in 
dry ice (-96°C) and later stored at -70°^ till the time of 
PG measurements. No attempt was made to dissect the 
gastric mucosa to avoid traumatizing the tissue, which 
could subsequently affect PG synthesis. The rest of the 
stomach was fixed in formalin/saline solution prior to 
histological assessment. All specimens, including the 
biopsies, were given code numbers to facilitate
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randomization.
Before testing for PG synthesis, the biopsies were 
thawed, weighed, and washed in 1 ml of phosphate buffered 
saline per biopsy for 5 minutes at 20°C to minimize 
measurement of PGs induced by trauma. The supernatant
was removed and 1 ml of fresh phosphate buffer was added. 
Tissues were then incubated at 37°C for 60 minutes. The 
supernatant was removed and mixed with an equal volume of
methyloximating agent (MOX) (96), left at 20°C overnight
and kept at 4°C till the time of the radio-immunoassay. 
The biopsies were taken for protein measurement (98) and 
the results were expressed in nanograms of PGE2 /mg 
protein. Details of the radioimmunoassay are as
described in Chapter 2. For histological assessment, 2 
longitudinal sections were made along the greater curve. 
They were processed routinely and stained with 
haematoxylin and eosin. The antral mucosal thickness was 
determined by taking the mean of 5-10 (average 7)
measurements from the luminal surface of the antrum to the 
upper border of the muscularis mucosae using an eye piece 
graticule on a calibrated microscope. The antrum was
chosen for histology because PGs were measured in antral 
tissue. The three oils used were analysed for their
basic fatty acid ingredients by gas-liquid-chromatography 
(G.L.C.). Statistical analyses involved the Mann-Whitney 
and Kruskal-Wallis tests where appropriate.
The study was carried out according to local ethical 
and Home Office regulations governing experiments on
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animals.
7.4. RESULTS.
After 6 weeks of taking different diets, the amount 
of weight gained by the four groups of rats were 
comparable (final weights of 200-250 g/rat) without any 
significant differences between the groups.
The basic fatty acid constituents of the oils studied 
are shown in Table 1. As expected, fish oil is rich in 
eicosapentaenoic and docosahexaenoic acids, while EPO and 
olive oil contain large amounts of linoleic and oleic 
acids, respectively. In addition, each of these oils 
contains, in smaller degrees, some other fatty acids which 
can be important in deciding the amount of PGs produced by 
the gastric tissue.
The amounts of PGE2 produced by various groups of 
rats and the mucosal thickness of these groups are shown 
in Figures 11 and 12. The diets used did not seem to
have any significant effect on the mucosal thickness after 
6 weeks, but all oil diets resulted in higher PGE2 values 
than the control group. It is also worth mentioning that 
the histological features were normal in all groups.
Since the mucosa was not dissected in the antral 
biopsies, the PGE2 measured reflects the activity of 
other tissues as well as the mucosa. This should not 
influence the interpretation of the results because the 
procedures were standardized in all groups.
TABLE 1
BASIC FATTY ACID CONSTITUENTS OF FISH, EVENING PRIMROSE AND 
OLIVE OILS AS DETERMINED BY GAS-LIQUID-CHROMATOGRAPHY.
(% of total weight)
Evening 
Fish Primrose Olive 
Fatty Acids Oil Oil Oil
Myristic Acid [Cj^.g] 13.3 - 0.2
Palmic Acid [Cig.g] 0.3 5 10
Palmit-oleic Acid 
[C16:1J
12.2 - 0.2
Hexadecdienoic Acid 
[C16:2!
13.3 — —
Stearic Acid [C^g.q ] 3.8 1.7 2.6
Oleic Acid [C-^g. ^ ] 16 9.5 80
Linoleic Acid [C^g.23 1.2 77 6.4
Linolenic Acid [C^g.3] 1 4 0.5
Arachidonic A c i d t^o*^ 5.6 - -
Eicosapentaenoic Acid 
^20:5^
27 - -
Docosapentaenoic Acid 
[C22:51
2.2 — -
Docosahexaenoic Acid 3.7 - -
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11. Gastric tissue PGE2 produced by study groups fed 
on fish oil, evening primrose oil and olive oil, 
as compared with controls.
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as compared with controls.
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7.5. DISCUSSION.
These results show that all the oils studied, 
including olive oil, are capable of increasing gastric 
PGE2 synthesis. The relatively low PGE2 production by 
the fish oil group could be as a result of the synthesis 
of PGE series with one or two extra bonds induced by 
highly unsaturated precursor acids (eicosapentaenoic and 
docosahexaenoic acids). Also, products from these 
precursors would not be detected as PGE2 . In this assay, 
there was 31% cross-reaction between PGE2 antiserum and 
PGE3 , the more likely product of fish oil. Since it is 
important to measure prostanoids induced by fish oil 
ingestion, a procedure like gas chromatography-mass 
spectroscopy would stand a better chance in distinguishing 
between PGE2 and PGEg than radioimmunoassay because of its 
high specificity.
The interaction between components of fish oil and PG 
synthesis might have more desirable effects in systems 
other than the gastric mucosa. Eicosapentaenoic acid is 
both a substrate (61) and an inhibitor of the cyclo- 
oxygenase pathway (62), whereas docosahexaenoic acid is 
simply an inhibitor (62). Thromboxane Ag derived from 
eicosapentaenoic acid is less active in aggregating
platelets than conventional TXA2 , an effect which helps 
prevent coronary heart diseases (12,61,62). It was
recently suggested that eicosapentaenoic acid can compete 
with arachidonic acid not only for metabolism by the
cyclo-oxygenase pathway but also for metabolism by the
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lipoxygenase pathway to leukotrienes, hence its beneficial 
effect in modifying immune and inflammatory responses 
(205). The animals were not subjected to any gastric 
injurious agents in this study. This is because many 
studies have already established the mucosal protective 
effect of PGs in general and PGE£ in particular against 
experimental injuries (211). Ethical issues were also 
considered in this context.
The study groups varied in numbers of animals as a 
result of randomization, but I accept that it is better 
to use equal numbers where possible.
In addition to their organ protective properties, PGs 
are said to exert a trophic effect on the gastric mucosa 
(38). An attempt was made to demonstrate this feature by 
measuring the mucosal thickness, but there was no 
significant differences between various diet groups. One 
reason for this might be because of the possibility that 
the 6 - week study was too short for gross structural 
changes to evolve.
It has been proposed that the marked increase in the 
dietary availability of essential fatty acids could be 
responsible at least in part for the marked decrease in 
the incidence and virulence of peptic ulcer disease in the 
Western World, probably because such diets are capable of 
inducing PG synthesis (63). Corn oil and safflower oil 
are the main sources of essential fatty acids in Western 
societies; they contain about 70% by weight linoleic acid
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which is comparable to that contained in EPO. It could
therefore be speculated that corn and safflower oils might 
have an effect on gastric PGE2 production similar to that 
of EPO.
In view of the above hypothesis (63), these results 
may have some clinical and nutritional implications. 
This is particularly true in the case of olive oil, 
provided that the results can be confirmed in humans. 
The incidence of peptic ulcer disease is also low in Italy 
(Bianchi Porro G, personal communication), where the 
consumption of olive oil is high. The rarity of peptic 
ulcer disease in Italy could be related to the ability 
of olive oil diets to stimulate gastric PG production, 
probably because of the presence of linoleic and linolenic 
acid in olive oil.
Moreover, olive oil is easier to produce, and is 
probably more palatable than fish oil or EPO. For these 
reasons, compliance with its intake might be easier to 
achieve. However, further studies are needed to see if 
these findings apply to humans.
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CHAPTER 8.
8. DUODENAL MUCOSAL PROSTAGLANDIN SYNTHESIS
IN PATIENTS WITH DUODENAL ULCERS.
8.1. SUMMARY.
The capacity of the duodenal mucosa to synthesise 
PGE2 , PGI2 and thromboxane A2 was tested in short term 
incubates of biopsies taken from duodenal ulcer patients 
and a group of controls without ulcers. The values of 
all prostaglandins tested were similar in both groups 
without any statistically significant differences. It 
was not possible to confirm findings of previous reports 
suggestive of a defect in the potential of human duodenal 
mucosa to synthesise prostaglandins in cases of duodenal 
ulceration. These findings might help explain, at least 
in part, the failure of the so-called "cytoprotective" 
doses of prostaglandin analogues in the treatment of 
duodenal ulcers.
8.2. INTRODUCTION.
A balance, probably dynamic in nature, normally 
exists between the duodenal mucosal resistance and 
potentially injurious luminal milieu, with mucosal 
resistance adapting to luminal conditions. Mucosal
resistance is not exclusively a function of individual 
surface cells, but rather a multifactorial property of the 
various mucosal layers, enabling the tissue to contain and 
quickly repair injury. The chief factors determining
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mucosal resistance are believed to be: the state of the
adherent mucus layer, mucosal bicarbonate secretion, blood 
flow and regenerative capacity. Local prostaglandin (PG) 
synthesis modulates some of these factors, but other 
mechanisms are also involved.
Ulcers occur when an imbalance allows luminal 
injurious factors to predominate over mucosal resistance. 
The chief injurious factors are acid and peptic activity. 
Bile reflux, drugs and stasis may alter the luminal milieu 
and act together with acid-peptic activity to induce 
injury, weaken mucosal resistance, or both.
Disturbances of protective mechanisms or enhanced 
injurious potential - some possibly genetically 
determined, others acquired - have been identified in 
ulcer patients. Since PGs modulate several key mucosal 
protective mechanisms, and some exogenous PGs or their 
derivatives accelerate healing of peptic ulcers, it 
follows that PG deficiency may contribute to the 
development of peptic ulcers. The evidence that such 
deficiency exists in duodenal ulcers has been indirect and 
has given rise to some disagreement amongst previous 
workers (64,76-78). Moreover, recent studies (51,212) 
have shown that PG analogues healed duodenal ulcers only 
when given in acid-inhibitory doses which are higher than 
those needed for cytoprotection, despite the multitude of 
favourable properties of such analogues (38).
The aim of this study is to see if a deficiency
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exists in the capacity of the duodenal mucosa of patients 
with duodenal ulcers to synthesis PGs, as compared with 
a group of control subjects without ulcers.
8.3. PATIENTS AND METHODS:
Patients with duodenal ulcers were entered into the 
study if they were 18-70 years old at the time of the 
diagnosis of their ulcers by endoscopy. They were
excluded if they took ulcer healing agents or NSAIDs 
within a week of the endoscopy or if they had any other 
systemic illness or infection. Patients with a history 
of previous gastric surgery or heavy alcohol intake (more 
than 1 0  units/week) were also excluded.
Control subjects were recruited after presenting with 
an indication for upper gastrointestinal endoscopy. The 
endoscopy and all other subsequent tests were normal. 
They were excluded if they had any of the drugs or the
exclusion criteria for duodenal ulcer patients mentioned
above. Subjects outside the age range of 18-70 were also 
excluded.
The endoscopy was performed after a 12-hour fast, and 
the intravenous administration of 5-15 mg diazepam.
Single biopsies weighing 5-10 mg were taken from the 
first part of the duodenum of the control subjects, and 
2 cm away from the ulcer edge in duodenal ulcer patients.
They were immediately frozen in dry ice (-96°C) and later
kept at -70°C till the time of PG assay.
Before testing for PG synthesis, the specimens were
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thawed, weighed, and washed in 0 . 5  ml per biopsy of 
phosphate buffered saline for 5 minutes. The supernatant 
was discarded as it is considered to contain PGs induced 
by trauma. The specimens were then incubated at 20°C for 
30 minutes and at 37°C for another 30 minutes. 0.5 ml of 
fresh buffer was added at the start of each stage of 
incubation, and the supernatant was removed at the end for 
methyloximation (details of this process, the subsequent 
radioimmunoassay and protein estimation are as described 
in Chapter 2). All specimens were assayed in duplicate 
under double-blind conditions.
Three classes of PGs were measured: PGE2 , PGI2 a^s 
oxo-PGF^ ), and thromboxane A£ (as TXB2 ). The results 
are expressed in ng/mg protein.
The Mann-Whitney test was used for statistical 
analysis.
Informed consents were obtained and the study was 
approved by the local Ethical Committee.
8.4. RESULTS.
A total of 27 duodenal ulcer patients and 21 control 
subjects were included; their demographic data are shown 
in Table 2. Both groups seem to be comparable as far as 
their ages and smoking habits are concerned. As expected, 
there are more males with duodenal ulcers, but the control 
group contains more females, possibly because the basic 
diagnosis in this group is that of probable irritable 
bowel syndrome.
TABLE 2
DEMOGRAPHIC DATA OF DUODENAL ULCER PATIENTS 
AND THE CONTROL SUBJECTS.
DUODENAL
ULCERS
CONTROLS
Males 18 7
Females 9 14
Age (years) 31 33
Median (range) (29-42) (23-42)
Smoking (cigarettes/day
Nil 6 9
less than 10 4 3
10-20 9 5
more than 20 8 4
Total Number 27 21
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The total amounts of PGs synthesised by both groups 
after 60 minutes of incubation are shown in Figure 13. 
There are no significant differences between duodenal PG 
synthesis in ulcer patients, as compared to the control 
group.
8.5. DISCUSSION.
The results show no evidence of any deficiency in the 
synthesis of PGE2 , PGI2 or T X B 2 in t*ie presence of 
duodenal ulceration; on the contrary PG values in ulcer 
patients tended to be higher than in the control group, 
possibly due to the presence of an element of duodenitis 
in the non-ulcerated or "healthy” looking mucosa from 
which the biopsies were taken. As in previous studies, 
however, no histological assessment was performed on 
representative duodenal tissue.
These findings are in agreement with those of some 
(76,78) but not all previous studies (77). In addition 
to their finding of unsuppressed PG values in duodenal 
ulcer patients, Ahlquist et al. (78) also showed that 
duodenal mucosal PGs in such patients failed to rise in 
response to the challenge with an acid load which might 
indicate a defect in the mechanism of mucosal adaptive 
cytoprotection.
Other workers showed low values of gastric antral PG 
synthesis in patients with duodenal ulcers (76), but the 
relevance of such finding is unclear.
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While agreeing with another previous report (77) 
that PGE2 and TXB2 synthesis remain intact in duodenal 
ulcers, its finding of a low PGI2 value could not be 
confirmed; the method used in that report to assess PG 
synthesis was in many respects similar to the one used by 
this study, at least as far as handling of the tissues is 
concerned. It is believed, however, that the assay used
in this study has the added advantage of a greater degree
of PG compounds stabilization by methyl-oximation (96).
The subjects investigated in the study were not on 
any therapy for at least one week before the biopsies were 
taken. The concurrent intake of some NSAIDs could have 
resulted in suppression of PG values, as in the case of 
findings obtained from experimental models using NSAIDs. 
This might have been the origin of the idea that PG 
synthesis is low in duodenal ulcers, which could not be
confirmed by many subsequent studies including this one.
This also highlights the importance of taking into 
consideration the drug history of patients included in PG 
assessments.
In conclusion, no evidence was found of PG deficiency 
in the duodenal mucosa of patients with duodenal ulcers. 
Such finding might be relevant to the interpretation of 
the results of other studies investigating the response of 
duodenal ulcers to the intake of PG analogues. As
mentioned earlier, these agents were effective only in 
acid-inhibitory doses (51,212), which are higher than the 
amounts needed for cytoprotection, possibly because PG
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synthesis is maintained in duodenal ulcer patients, as 
shown by this study.
SECTION 3.
ANTI-ARTHRITIC AND GASTRO-DUODENAL RESPONSES 
TO NAPROXEN AND ETODOLAC THERAPY. EFFECTS 
ON ENDOSCOPIC APPEARANCE, HISTOLOGY,
AND PROSTAGLANDIN SYNTHESIS.
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SECTION 3. ANTI-ARTHRITIC AND GASTRO-DUODENAL
RESPONSES TO NAPROXEN AND ETODOLAC THERAPY. 
EFFECTS ON ENDOSCOPIC APPEARANCE, HISTOLOGY, 
AND PROSTAGLANDIN SYNTHESIS.
INTRODUCTION.
This section investigates a range of activities of 
two NSAIDs: a new preparation, etodolac, is compared to an 
established agent, naproxen. From the point of view of 
patients with an indication for their use, such as active 
rheumatoid arthritis, the anti-arthritic activity of these 
agents probably comes first in the order of priorities. 
Gastro-duodenal side effects, especially dyspeptic 
symptoms, might come second. These parameters are
measured in Chapter 9. Mucosal PGs are measured in 
Chapter 10, to see if this could explain the differences 
between naproxen and etodolac regarding their effects on 
the gastric and duodenal mucosa. To put PG results in 
context, and to facilitate their interpretation, other 
responses are also included such as the anti-arthritic 
activities, the endoscopic scores and histology.
CHAPTER 9
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9. EVALUATION OF THE EFFICACY AND COMPARATIVE
EFFECTS ON GASTRIC AND DUODENAL MUCOSA OF 
ETODOLAC AND NAPROXEN IN PATIENTS WITH 
RHEUMATOID ARTHRITIS USING ENDOSCOPY.
9.1. SUMMARY.
The therapeutic efficacy and upper gastrointestinal 
side effects of a twice daily dose of 300 mg etodolac and 
500 mg naproxen were compared in 30 hospital out-patients 
with active rheumatoid arthritis. Drugs were taken for 4 
weeks in a double-blind, randomised, parallel group, 
single centre study. Rheumatological, endoscopic and 
laboratory assessments were performed at the start and on 
completion of the study.
Mucosal lesions developed in only 3 patients (20%) of 
the etodolac group and they all had low endoscopy scores, 
compared to 8 patients (53%) of the naproxen group with 
significantly worse endoscopy scores (p<0.05). Lesions 
were asymptomatic in all but one patient (on naproxen), 
and the gastric antrum was the commonest region involved. 
Of the 11 patients who developed endoscopic abnormalities 
in both groups, 7 (64%) were moderate to heavy smokers. 
Etodolac had a similar anti-arthritic effect to naproxen, 
but it appears to be better tolerated by the upper gastro­
intestinal mucosa as shown by endoscopy.
9.2. INTRODUCTION.
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There is a continuous demand for an alternative anti­
inflammatory therapy with a lesser damaging effect on the 
gastro-duodenal mucosa in patients with chronic arthritic 
diseases like rheumatoid arthritis. The unreliability of 
upper abdominal symptoms as indicators of NSAID-induced 
mucosal damage makes it important to use endoscopy for 
assessment of the possible side effects of NSAIDs 
especially the newer preparations. Etodolac (Lodine^\ 
Ultradol^^) is the first of a new class of non-steroidal 
anti-inflammatory drugs, the pyranocarboxylic acids, which 
has been shown to be effective in relieving symptoms of 
rheumatoid arthritis (213,214) and osteoarthritis. The 
chemistry of etodolac is shown in Figure 14. Comparing 
it to naproxen, a propionic acid derivative with 
established efficacy in inflammatory arthritic disorders 
(215), previous studies found no clinically significant 
differences in efficacy or in the recorded number of 
complaints in rheumatoid arthritis (216), although normal 
volunteers taking etodolac showed better endoscopic scores 
than those taking naproxen (217). This study aims at 
comparing the two drugs in patients with active rheumatoid 
arthritis in respect of their anti-arthritic activity and 
their effect on the gastro-duodenal mucosa as judged by 
endoscopy over a 4 week period.
9.3. PATIENTS AND METHODS.
Informed and written consents were obtained, and
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patients were included only after ensuring that they 
fulfilled the criteria set by the American Rheumatism 
Association for the diagnosis of rheumatoid arthritis, if 
they were in Functional Class I, II, or III, and if they 
showed evidence of disease activity as suggested by all of 
the following: (i) number of tender or painful joints on
motion - 5 or more, (ii) number of swollen joints - 3 or 
more, and (iii) duration of morning stiffness - 30 minutes 
or more.
Patients were excluded if their arthritis started 
before the age of 16, if they had any other systemic 
disease that involved the kidneys, liver or cardio­
vascular systems, if they were known to have allergic 
reactions or disease, or if they had a definite or 
presumptive diagnosis of peptic ulceration. Drugs like 
sulphasalazine, systemic or intra-articular steroids, 
cytotoxics, and peptic ulcer healing agents were not 
allowed and patients taking them prior to the study were 
excluded. Patients receiving gold, salts, penicillamine 
or antimalarials were admitted provided that: (a) these
agents were started at least 6 months prior to entry into 
the study, (b) dosage regime had remained fixed for the 2 
months prior to entry into the study and would not be 
changed for the duration of the study and, (c) dosage 
of the antimalarial did not exceed 400 mg of 
hydroxychloroquine per day.
Suitable patients were asked to discontinue their 
current non-steroidal anti-inflammatory drugs and were
137
provided with paracetamol to take during a wash out period 
of about 4-7 days, after which they reported for their 
first visit and endoscopy. Both naproxen and etodolac 
were presented as grey capsules that looked identical to 
one another. They carried code numbers to facilitate 
randomization. Study medications were delivered in a 
double-blind fashion at doses of 300 mg twice daily of 
etodolac and 500 mg twice daily of naproxen together with 
a bottle of paracetamol, as an 'escape' analgesic, for a 
total of 4 weeks. The number of unused medications 
including paracetamol was noted by tablet count on the 
second visit on completing the study. Patients were 
dropped from the study if their initial endoscopy showed 
any abnormality, if they demonstrated non-compliance, 
developed intercurrent illness, did not get adequate 
relief from the study medication, or if they experienced 
serious adverse reactions.
9.3.1. Clinical Assessments:
These were performed on day one, immediately before 
issuing the study medications, and four weeks later. 
They included: (i) general medical history and physical
examination, (ii) duration of morning stiffness (in 
minutes), (iii) grip strength (in mmHg), (iv) investigator 
and (v) patients evaluation of global condition (very 
good, good, fair, poor, very poor), (vi) articular index 
(218), (vii) laboratory tests including full blood count, 
biochemical screen, urinalysis, ESR, and (viii) endoscopy. 
Endoscopy was performed by a single operator (myself) on
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both visits, and findings recorded on a 0 - 5 scale,
modified from Lanza (217), for the oesophagus, duodenum 
and each region in the stomach; 0 score: normal, 1 : any 
erythematous change, 2 : submucosal haemorrhage, 3 : single 
erosion, 4: multiple erosions, and 5: frank ulceration.
9.3.2. Statistical Analyses:
The significance of the degree of change in results 
of the clinical assessments between the two visits within 
each group, was tested using the Wilcoxon ranked and sign 
tests. Endoscopy scores were compared using the Mann- 
Whitney test between the two groups.
9.4. RESULTS.
Thirty-two patients entered the study, but two were 
excluded from the analysis; one patient who failed to 
attend the final visit and one who took medications 
prohibited by the protocol. It is also worth mentioning 
that 3 patients were not entered because of initial 
endoscopic abnormalities. Minor endoscopic lesions could 
have also existed in some of the study patients, but must 
have spontaneously disappeared during the washout period. 
The demographic data for the remaining 30 patients is 
presented in Table 3; the two groups were not 
significantly different in their baseline characteristics.
9.4.1. Compliance:
Patients in the naproxen group took a median of 90% 
of the number of naproxen tablets supplied (82-94%, 
interquartile ranges) and 57% (15-74%) of the paracetamol
TABLE 3
DEMOGRAPHIC DATA FOR 30 PATIENTS ANALYSED: 
MEDIAN (INTERQUARTILE RANGES) FOR AGE AND 
DURATION OF ARTHRITIS.
PATIENTS NAPROXEN ETODOLAC
Number studied 15 15
Sex: Male 5 4
Female 10
Age (years) 57 (45-65) 50 (41-63)
Duration of Rheumatoid 
Arthritis (years) 6 (4-8) 11 (5-17)
On 2nd line drugs 10 8
Previous NSAID intake 12 12
Smokers: Light
Moderate^
Heavy
1 2
4 5
2 1
Alcohol 8 7
(1): less than 5 cigarettes/day
(2): 5-20 cigarettes/day
(3): more than 20 cigarettes/day.
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provided; this is compared to 87% (86-90%) of etodolac 
and30% (3-49%) of paracetamol, respectively in the 
etodolac group. This suggests that compliance was fairly 
good in both groups but patients on etodolac needed less 
paracetamol.
9.4.2. Efficacy Assessment (Table 4).
Baseline values were comparable in both groups 
without any statistically significant differences. 
Significant improvements were observed in the duration of 
morning stiffness and articular index in both treatment 
groups. Patients treated with naproxen also showed a 
significant improvement in right-hand grip strength, which 
was not found in the etodolac group. When the results 
for this parameter were compared between the two groups, 
there was a significant advantage for naproxen (p=0.03, 
Mann-Whitney).
9.4.3. Endoscopy Results (Table 3).
None of the patients receiving etodolac had an 
endoscopic score greater than 3 (single erosion in one 
area) at the 4 week assessment. Indeed, twelve out of 
the fifteen patients in the group had a score of zero 
(normal mucosa in all regions) at that time. This is in 
contrast to the naproxen group where one patient developed 
frank ulceration, and a further six had multiple erosions. 
These differences in the scores between the two groups 
were statistically significant (p<0.05).
It is of interest to note that only two patients
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TABLE 4
DURATION OF MORNING STIFFNESS, GRIP STRENGTH, 
ARTICULAR INDEX: MEDIAN AND INTERQUARTILE RANGES.
NAPI10XEN ETOl)0LAC
WEEK 0 WEEK 4 WEEK 0 WEEK 4
Duration of morning 
stiffness (minutes) 90(60-180) 50(5-120)** 60(50-120) 30(5-60)**
Grip Strength(mmHg) 
Right hand 
Left hand
81(59-104)
77(69-129)
103(63-163)*
101(72-150)
73(61-111)
87(66-114)
78(70-112)
94(68-133)
Articular index 13(10-21) 10(7-11)* 13(9-17) 7(4-12)*
ESR
(mm/hr)
18.5(7-34) 17(9-27) 22(7-39) 18(6-34)
* = O.Ol < p<0.05
** = 0.001 < p<0.01
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TABLE 5
DISTRIBUTION OF PATIENTS ACCORDING TO FINAL 
ENDOSCOPY SCORES PER EACH ANATOMICAL REGION.
NAPROXEN (n= 15) ETODOLAC (n= 15)
SCORE 0 _1 2 2 _4 2 0 2 2 2 4_ 2
Oesophagus 15 0 0 0 0 0 15 0 0 0 0 0
Greater Curve 14 0 1 0 0 0 13 1 0 1 0 0
Lesser Curve 14 0 1 0 0 0 15 0 0 0 0 0
Antrum 9 0 0 1 4 1 14 0 0 1 0 0
Pylorus 13 0 0 1 1 0 15 0 0 0 0 0
Duodenum 
(first part) 14 0 0 0 1 0 15 0 0 0 0 0
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complained of GI symptoms, both receiving naproxen, and 
only one of them showed lesions on endoscopy. Also, the 
majority of lesions were in the stomach, particularly in 
the antrum, with only one patient having multiple erosions 
in the duodenum.
Seven of the eleven patients (64%) who developed 
abnormal endoscopic findings were moderate to heavy 
smokers (Table 3). In four of them (57%) the lesions 
were found in the gastric antrum.
9.4.4. Laboratory Evaluations:
No significant changes or abnormalities were noted in 
any of the laboratory evaluations. The ESR did not 
change between the baseline and the 4 week visit.
9.5. DISCUSSION.
The efficacy of etodolac, 300 mg twice daily, seems 
to be comparable to that of naproxen 500 mg twice daily, 
but the numbers of patients involved in this study are too 
small to make a strong statement regarding efficacy. The 
overall results are in agreement with a similar recent 
study (216) that included a slightly bigger number of 
patients.
The results, also, show that etodolac is tolerated 
better by the stomach than naproxen as revealed by the 
endoscopic findings. A similar effect on the gastro­
duodenal mucosa was also found in normal volunteers who 
took the drugs for a shorter period (217,219). The 
reason for such an effect is unclear, but it is
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interesting to note that previous workers demonstrated 
that the amount of gastrointestinal microbleeding produced 
by etodolac did not differ from that seen with placebo and 
was significantly less than that seen with some other 
NSAIDs (220-222). It was also shown that etodolac, at a 
low dose, reduced gastric PGE2 levels significantly less 
than naproxen or piroxicam in rats (223), though at a 
higher dose all three drugs produced similar reductions in 
PGE2 levels. It is not known whether these findings in 
rats can be extended to humans, and further studies in 
this field may be worthwhile. Some of these aspects will 
be considered in Chapter 10.
These results are also in agreement with previous 
studies suggesting that patients taking non-steroidal 
anti-inflammatory drugs tend to develop asymptomatic
lesions (224,225), and that such lesions affect the
stomach in most cases (226), particularly the antrum
(227). It also seems that smokers tend to develop their 
lesions in the antrum more than any other region in the 
stomach (227). It is clear however that the findings
here are based on a short term study, and long term data 
on the safety of both naproxen and etodolac are required.
In conclusion, etodolac appears to have a less 
damaging effect on the stomach. These results, together 
with the findings of previous microbleeding studies, 
identify etodolac as a potentially useful agent in the 
treatment of rheumatoid arthritis.
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CHAPTER 10.
10. THE EFFECT ON GASTRIC AND DUODENAL MUCOSAL
PROSTAGLANDINS OF REPEATED INTAKE OF THERAPEUTIC 
DOSES OF NAPROXEN AND ETODOLAC IN RHEUMATOID ARTHRITIS.
10.1. SUMMARY.
The synthesis of gastric and duodenal mucosal 
prostaglandin E£ (PGE2 ), PGI2 , Thromboxane (TXB2 ) during a 
60 minute incubation of biopsy specimens, the degree of 
endoscopic and histological damage, and the anti­
inflammatory response were all studied after a four-week 
double-blind study of therapeutic doses of 2 non-steroidal 
anti-inflammatory drugs, naproxen and etodolac, received 
by 27 patients with active rheumatoid arthritis (13 
receiving naproxen, 14 etodolac). Post-treatment PG
values were not different from the baseline levels when 
all the patients were analysed as one group. Subgroup 
analysis showed that naproxen suppressed gastric PGE2 from 
a median of 29 to 9 ng/mg protein (p<0.01), duodenal PGE2 
from 34 to 11 (p<0.01) and duodenal PGI2 from 62 to 15 
ng/mg protein (p<0.05). No overall suppression occurred 
with etodolac. Also, on the second assessment patients 
receiving naproxen had lower gastric and duodenal PGE2 and 
PGI2 , but higher values of duodenal TXB2 , than patients 
receiving etodolac. Both drugs had similar anti-
arthritic activity and caused microscopic gastritis in 
similar proportions of patients. No correlation was
146
detected between PG values and the mucosal damage which 
developed in 7 patients on naproxen (54%) and 3 patients 
on etodolac (21%).
These findings indicate that, unlike naproxen, etodolac 
does not seem to affect gastric or duodenal PG synthesis; 
other mechanisms of injury need to be considered.
10.2. INTRODUCTION.
It has been increasingly recognized that NSAIDs and 
prostaglandins (PGs) have opposite effects on the 
defensive mechanisms of the gastric mucosa (38,228). One 
of the theories proposed to explain the mechanism of 
NSAIDs induced damage is their ability to suppress 
mucosal PG synthesis (89,229). Most knowledge in this 
field has come from animal work (223,229-232), or from 
studies of young, healthy human volunteers given single 
doses or short term courses of aspirin or indomethacin 
(91,233). When patients with rheumatic disorders were 
studied (90), basal values of the ability of the gastro­
duodenal mucosa to synthesise PGs were not known, and the 
precise nature of their disease was not adequately 
described.
Etodolac is a member of a new class of NSAIDs, the 
pyranocarboxylic acids; it has been reported to be better 
tolerated by the stomach than naproxen, a propionic acid 
derivative with established efficacy in arthritis, but 
both agents were reported to have a comparable anti- 
arthritic activity (216,217, Chapter 9 in this Thesis). A
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recent animal study has suggested that the different 
effect of these two agents on the gastric mucosa could be 
due to the sparing of gastric PG synthesis by etodolac 
(223).
The purpose of this prospective double-blind single 
centre study is to assess the effect of four weeks' 
treatment with therapeutic doses of naproxen and etodolac 
in patients with active rheumatoid arthritis on gastro­
duodenal mucosal PG synthesis, anti-inflammatory activity, 
and endoscopic and histological changes.
10.3. SUBJECTS. MATERIALS AND METHODS.
10.3.1. Rheumatoid Arthritis Patients:
The patients studied were 18-70 years old, with 
active rheumatoid arthritis according to the criteria of 
the American Rheumatism Association. Patients receiving 
second-line agents, gold, penicillamine or hydroxy­
chloroquine but not sulphasalazine, were included if such 
drugs were previously started 6 months or longer prior to 
the study, and the doses had been unchanged for 2 months 
before the study. Sulphasalazine was excluded because 5- 
10% of its 5-aminosalicylic acid component is absorbed, 
which might affect PG production, although there is no 
evidence for this. Subjects on NSAIDs underwent a
washout period of at least 5-7 days prior to receiving the 
study medications, during which time paracetamol was used 
as an analgesic agent. Preliminary work showed that 
there was no significant difference in gastric or duodenal
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mucosal PG synthesis between arthritic patients who 
stopped receiving NSAIDs for 4 days and controls who were 
not receiving NSAIDs. Patients were excluded if they
had any abdominal complaints, a history of peptic 
ulceration or any systemic diseases. Those taking 
cytotoxic agents, steroids, or ulcer healing drugs were 
also excluded.
10.3.2. Study Medications:
Naproxen 500 mg bd and etodolac 300 mg bd, prepared 
as identical capsules, were given in a double-blind 
randomised design for a period of 4 weeks, with
paracetamol used as a baseline analgesic. Compliance was 
checked using a tablet count.
10.3.3. Assessments:
Assessments were made on 2 visits, just before the 
start of the study drugs and on completion 4 weeks
later. They included a general medical history and
examination, assessment of the activity of the rheumatoid 
arthritis, and endoscopy. Rheumatoid disease activity 
was assessed by measuring the ESR, grip strength (mmHg), 
the Ritchie articular index (218), the duration of morning 
stiffness, and both the patients and investigator’s 
evaluation of the global condition. Endoscopy was
performed after the intravenous administration of 5-15 mg 
of diazepam. Endoscopic abnormalities were graded
according to a (0-5) scale modified from Lanza (219); 0
score: normal, 1: any erythematous changes, 2: sub-mucosal
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haemorrhage, 3: single erosion, 4: multiple erosions, and 
5: frank ulceration.
Patients showing any abnormal endoscopic findings at 
the initial visit were not admitted to the study. On both 
visits biopsies weighing 5-10 mg were taken from healthy 
looking mucosa in the gastric antrum and the first part of 
the duodenum for prostaglandin assays and for histology. 
All assessments were done under double-blind conditions. 
Suitable patients were given the study medications within 
12 hours of completing the initial assessment.
10.3.4. Histology:
Specimens were fixed in formalin buffered saline, 
embedded in paraffin wax and 5 urn sections prepared for 
light microscopy. Sections were stained with
Haematoxylin and Eosin. Histological appearances were 
broadly divided into mild or severe inflammation: mild
inflammation referred to the presence of few inflammatory 
cells in the lamina propria, while severe inflammation 
meant that there was extensive inflammatory infiltration 
of the lamina propria, glands and crypts (149).
10.3.5. Prostaglandin Assays:
Biopsy specimens were taken and immediately frozen 
in liquid nitrogen and stored at -70°C. Each specimen 
was later thawed, weighed and washed in 0.5 ml of 
phosphate buffer per biopsy for 5 minutes at room 
temperature to remove the debris and minimize measurement 
of PGs induced by trauma. The supernatant was removed
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and specimens were incubated at 20°C for 30 minutes and at 
37°C for another 30 minutes. Fresh phosphate buffer (0.5 
ml) was added at the start of each step of incubation, and 
the supernatant removed at the end of each stage to be 
mixed with an equal volume (1:1) of methyloximation agent 
(96), left overnight at room temperature, and stored after 
that at 4°C till the time of radioimmunoassay. Three 
PGs were measured: PGE2 , PGl2 »and Thromboxane A2 . PG^
and Thromboxane A2 were measured as their stable 
metabolites 6-oxo-PGF-^ and TXB2 respectively. Full
details of the radioimmunoassay are described in Chapter 
2. The protein content of each biopsy was measured as 
described by Lowry (98), and the results of prostaglandin 
synthesis are expressed in ng PG/mg protein.
10.3.6. Statistical Analyses:
These were performed using the Wilcoxon signed ranks 
and the Mann-Whitney tests, where appropriate. P values 
of less than 0.05 were regarded as significant. 
Correlation between PG values and endoscopic scores was 
tested using Spearman's rank-correlation coefficient.
Informed consents were obtained and the study was 
approved by the local Ethical Committee.
10.4. RESULTS.
Twenty-seven patients completed the study; 13 (9
females, 4 males) median age of 60 years, were found to 
have been on naproxen, and 14 (10 females, 4 males) median 
age of 50 on etodolac. Three further patients were not
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entered into the study because their initial endoscopy was 
abnormal and 2 other patients dropped out before 
completing the study owing to protocol violations. In 
the naproxen group, 6 patients smoked, 9 were on second- 
line drugs and 10 had previous exposure to NSAIDs, 
compared to 7, 8, and 11 patients in the etodolac group 
respectively. Compliance was good and comparable in both 
groups (median of 89% of naproxen tablets and 87% of 
etodolac provided were taken).
10.4.1. PG Synthesis:
Baseline values were similar in both groups. Taking 
all rheumatoid patients as one group, there was no 
significant change in gastric or duodenal PG values before 
or after NSAID treatment. Significant differences became 
noticeable after patients were classified according to 
whether they received naproxen or etodolac (Figures 15- 
17); gastric PGE2 , duodenal PGE2 and PGI2 were all 
suppressed by naproxen. Etodolac seemed to have no effect 
on prostaglandin values. In addition, compared with
etodolac patients on the second assessment, naproxen 
patients had lower gastric and duodenal PGE2 and PGI2 but 
higher values of duodenal TXB2 .
10.4.2. Anti-arthritic Activity.
The extent of improvement in the indices of 
rheumatoid disease activity is shown in Tables 6 and 7; 
all variables improved after treatment but not necessarily 
to a significant degree, apart from the duration of
p
<
0
.
0
1
 
 
p 
<
0
.
0
1
(W
il
co
xo
n'
s)
 
 ^
f 
^
152
ursq.ojd §tu/§u ‘ 3Dd
Fi
g.
 
15
. 
Ga
st
ri
c 
an
d 
du
od
en
al
 
P
G
E
2 
at
 
ba
se
-l
in
e 
an
d 
af
te
r 
4 
we
ek
s 
of
 
tr
ea
tm
en
t 
wi
th
 
na
pr
ox
en
 
or
 
e
t
o
d
o
l
a
c
.
p<
0.
05
(W
il
oo
xo
n'
s)
153
CO
•rH
-p10)
*8
o
cd
r-H
o
’do
p
0)
p
o
P3
<U
*
O
}-iCu
cd
3
.3
P
•H
£
p
£<l)ep
cd<yu
p
<po
CO
<U0)
£
A 4A AA A
J2I
$
I
CO
•rH
p
a
•rH
b
8 8 £ 8 8 8 8
u
o
p
ip
cd
Td
a
cd
a)
a
•H
a)co
cd
p
p
cd
OPm
cd
3
<uTd
o
3
•d
Td
3
cd
o
•H
u
pco
cd
O
ui0q.oad §Lu/§a ‘SifH
v£>
W)
•H
p<
^"
0.
05
, 
M
a
n
n
-
W
h
i
t
n
e
y
154
* 
Na
pr
ox
en
 
— 
 
Et
od
ol
ac
 
 
 
Na
pr
ox
en
 
 
 
 
Et
od
ol
ac
--
--
--
--
 
 
 
Ga
st
ri
c 
ti
ss
ue
 
 
 
Du
od
en
al
 
ti
ss
ue
--
--
--
--
--
--
--
--
--
Fi
g.
 
17
. 
Ga
st
ri
c 
an
d 
du
od
en
al
 
T
X
B
2 
a
t 
ba
se
-l
in
e 
an
d 
af
te
r 
4 
we
ek
s 
of
 
tr
ea
tm
en
t 
wi
th
 
na
pr
ox
en
 
or
 
e
t
o
d
o
l
a
c
.
155
TABLE 6.
DURATION OF MORNING STIFFNESS, GRIP STRENGTH, 
ARTICULAR INDEX AND ESR BEFORE AND AFTER TREATMENT: 
MEDIAN AND INTERQUARTILE RANGES.
ALL RHEUMATOID 
PATIENTS (n=27
NAPROXEN GROUP 
(n=13)
ETODOLAC GROUP 
(n=lA)
Baseline A weeks Baseline A weeks Baseline A weeks
Duration of 
morning stiffness 
(minutes)
60
(60-120)
30*
(5-60)
90
(60-150)
50**
(17-90)
60
(A8-105)
30** 
(12-55 )
Grip Strength 
(mmHg)
Right hand 7A
(60-105)
83
(63-135)
7A
(60-102)
102
(60-15A)
76
(59-126)
81
(71-120)
Left hand 80
(68-116)
9A
(72-1AA)
77
(65-129)
93
(67-17A)
88
(67-130)
96
(70-139
Articular Index 13
(10-19)
g***
(5-11)
16
(10-22)
10
(7-12)
13
(9-18)
6
(3-11)
ESR
(mm/hr)
22
(7-39)
17
(8-33)
23
(10-36)
17
(9-3A)
18
(7-A1)
16
(5-35)
Significant improvement: * p<0.001, ** p<0.01, *** p<0.05
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TABLE 7
PAIN INTENSITY \  INVESTIGATOR'S OPINION^**\ 
AND PATIENT'S SELF-ASSESSMENT'**',
MEDIAN AND INTERQUARTILE RANGES.
ALL RHEUMATOID 
PATIENTS (n=27
PATIENTS ON 
NAPROXEN (n=13)
PATIENTS ON 
ETODOLAC (n=14)
Baseline 4 weeks Baseline 4 weeks Baseline 4 weeks
Pain Intensity 3
(3-4)
3
(2-3)
3
(3-4)
3
(2-4)
3
(3-4)
3
(2-3)
Investigators
Opinion 3
(2-3)
2
(2-3)
3
(2-3)
2
(2-3)
3
(2-3)
2
(2-3)
Patients' self 
Assessment 3
(2-3)
3
(2-3)
3
(2-3)
3
(2-4)
3
(2-3)
3
(2-3)
(*) 1: none, 2: mild, 3: moderate, 4: severe, 5: very severe.
(**) 1: very good, 2: good, 3: fair, 4: poor, 5: very poor.
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morning stiffness (p<0.001) and the articular index 
(p<0.05). The overall results indicate that, in this 
small group of patients, naproxen and etodolac have a
similar anti-inflammatory activity.
10.4.3. Endoscopic and Histological Changes:
The second endoscopy was abnormal in 7 patients on 
naproxen (54%) with a median score of 2 (0-4),
(interquartile ranges), compared to 3 on etodolac (21%) 
and a score of 0 (0-1) (p<0.05). Lesions developed in the 
stomach in all 10 cases except 1 (on naproxen) who had 
them in both the stomach and the duodenum. Only 3
patients (on naproxen) developed upper abdominal 
complaints, and the rest were all asymptomatic. PGs were 
not suppressed in the 3 patients with endoscopic 
abnormalities due to etodolac. The number of patients 
with severe inflammation in their gastric biopsies rose 
from 3 (23%) to 10 (76%) after taking naproxen, and from 4
(35%) to 11 (79%) after etodolac therapy. There was no
correlation between PG values and the degree of endoscopic 
damage (r= -0.3196 for PGE2 , -0.3793 for PGI2 and -0.2339 
for TXB2 in the entire population of rheumatoid patients). 
Also, no significant correlation was found between 
PGE2 /TXB2 ratio and the endoscopic scores (r= -0.2495). 
Both gastric and duodenal PGE2 /TXB2 ratios were 
significantly higher in patients receiving etodolac than 
in those who took naproxen (p<0.005). From these results 
it seems that there should be some form of negative 
correlation between endoscopic scores and PGE2 /TXB2 ratio,
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as patients receiving naproxen appear to have lower ratios 
and higher scores. This could not be proved, however, as 
no correlations were significant.
10.5. DISCUSSION.
This study demonstrates that, unlike naproxen, 
etodolac does not suppress gastric or duodenal PG 
synthesis. In this respect these results disagree with 
most of the available data obtained from studies on 
gastric PGs in patients with rheumatic diseases or those 
receiving NSAID therapy; such studies (87,90) have shown 
that the NSAIDs tested do suppress gastric PGs. The 
effects of individual NSAIDs were not known in those
reports, baseline PGs were not measured, and the number of 
patients taking the same agent was small.
Patients on naproxen had both a greater number of 
endoscopic abnormalities and lower PG values. Possibly,
these two events were inter-related, but this study was 
unable, like others (91), to demonstrate a correlation
between the endoscopic scores and PG values. Gastritis
(87) does not adequately explain the sparing of PG by 
etodolac, as inflammation was present in similar numbers 
of patients who took either agent. The significance of 
this gastritis is unclear; it was not evident on 
endoscopic examination, and was only revealed by 
histology.
Possibly, agents like etodolac might be selective in 
their effects on various tissues and different types of
159
PGs. Such an effect was previously described with
salicylic acid which caused preferential reduction in PGE2 
in sheep vesicular tissue, while indomethacin suppressed 
all classes of PGs (122). As mentioned in Chapter 3, 
NSAIDs vary in their capacity to inhibit PG synthesis 
(119,234). Indomethacin, naproxen and meclofenamic acid 
are powerful inhibitors of PG synthesis, phenylbutazone is 
a moderate inhibitor, while salicylic acid, aspirin and 
benoxaprofen are only weak inhibitors. Other drugs act 
as prodrugs that show activity through their metabolites: 
one of these agents is suldinac whose sulphide metabolite 
is a potent PG inhibitor (120). Animal studies (223) have 
also shown that acute exposure to naproxen or piroxicam 
reduced gastric PGE2 to a greater extent than etodolac, 
although at high doses all three drugs produced similar 
reductions in PGE2 .
The fact that PGs were not suppressed in patients who 
developed endoscopic abnormalities due to etodolac might 
mean that the mucosa recovered its capacity to synthesise 
PG prior to full healing of erosions, though this study 
has not shown that such capacity was lost to begin with, 
or that mechanisms other than PG deficiency were involved 
in causing gastric damage: in theory, these could include 
increased mucosal permeability (235), interference with 
active ion transport (236), redistribution of mucosal 
blood flow (237), capillary stasis (238), or by 
interfering with the mucus layer (239).
Little is known about the duodenal mucosal PG
160
response to the intake of NSAIDs, as most studies 
concentrated on their effect on the gastric mucosa 
(91,229-231,233), possibly owing to the fact that the 
stomach is more commonly affected by NSAIDs than the 
duodenum as shown by this study and by others (226). 
Like one of the previous studies on patients with duodenal 
ulcers (77), these results might suggest that the duodenal 
mucosal potential to synthesise PGI2 becomes limited in 
the presence of ulceration or when subjected to naproxen. 
Duodenal PGE2 was also suppressed in the patients taking 
naproxen, but not in those of Hillier et al. (77), the 
difference probably being due to the fact that their 
patients did not take NSAIDs. However, patients with 
duodenal ulcers studied in Chapter 8 had no PG deficiency 
in the absence of NSAIDs.
It is also interesting to find that patients who took 
naproxen had higher values of TXB2 (the stable metabolite 
of TXA2 ) than those receiving etodolac. Animal studies 
have suggested that vasoconstriction with TXA2 induces 
ulceration of the gastric mucosa (240), and that the 
selective inhibition of its synthesis results in gastric 
mucosal protection (241). The effect of TXA2 on the 
duodenal mucosa was not clarified by those workers. This 
study found that both gastric and duodenal PGE2 /TXB2 
ratios were higher in patients taking etodolac than in 
those receiving naproxen. The significance of this is 
not fully clear but it may explain, at least in part, the 
greater damaging effect of naproxen, though this study
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could not show a significant correlation between PGE2 /TXB2 
ratio and the endoscopic scores. The above studies
(240,241) also demonstrate that effective inhibition of 
TXA2 requires the use of specific inhibitors of 
thromboxane synthetase enzyme. Several studies have
shown that TXA2 synthesis might be maintained even when 
other cyclo-oxygenase products are suppressed (77,87,90).
In conclusion, after 4 weeks of regular intake in 
therapeutic doses, naproxen suppressed gastric PGE2 , 
duodenal PGE2 and PGI2 , while etodolac did not. At the 
same time, etodolac caused a lesser degree of endoscopic 
damage than naproxen; this could be related to their 
different effects on PGs, though there was no correlation 
between PG values and endoscopic scores. If it is
assumed that more NSAIDs assessed along the same lines of 
this study would have a similar behaviour to either 
naproxen or etodolac, these results may indicate that not 
all NSAIDs suppress gastric or duodenal PGs. Other modes 
of interaction between NSAIDs and the gastric mucosa need 
to be considered.
SECTION 4.
HELICOBACTER PYLORI AND THE GASTRIC MUCOSA. 
INTERACTION WITH INDOMETHACIN, AND EFFECTS 
ON THE PRODUCTION OF PROSTAGLANDINS AND 
CYCLIC AMP.
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SECTION 4. HELICOBACTER PYLORI AND THE GASTRIC
MUCOSA. INTERACTION WITH INDOMETHACIN AND 
THE EFFECTS ON THE PRODUCTION OF PROSTAGLANDINS 
AND CYCLIC AMP.
INTRODUCTION.
This section investigates some aspects of the 
interaction between H. pylori and the gastric mucosa, with 
special emphasis on the possible role of PGs. Chapter 11 
measures gastric PG synthesis in patients with gastric 
ulcers and non-ulcer dyspepsia, in the presence or absence 
of H. pylori. It also highlights the influence of
gastritis on PG production. Some aspects of the three 
main topics covered in this Thesis, PGs, NSAIDs, and H. 
pylori, are assessed together in Chapters 12 and 13. 
Chapter 12 investigates the possible interaction between 
H. pylori culture filtrate and indomethacin, using mucosal 
histology and PGE2 production as indices of such 
interaction. In Chapter 13, H. pylori culture filtrate 
is purified and a protein is obtained. The effect of 
this protein on mucosal cyclic AMP and PGE2 production is 
also investigated.
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11. GASTRIC MUCOSAL PROSTAGLANDIN SYNTHESIS IN THE 
PRESENCE OF HELICOBACTER PYLORI IN PATIENTS 
WITH GASTRIC ULCERS AND NON-ULCER DYSPEPSIA.
11.1. SUMMARY.
It is not clear whether Helicobater pylori (H. 
pylori) affects gastric mucosal prostaglandins (PG). In a 
double-blind study gastric PG synthesis was measured in 22 
patients with benign gastric antral ulcers (GU) and 26 
with non-ulcer dyspepsia (NUD). The presence of H.
pylori was determined by histology and bacteriology: 26 
(16 GU + 10 NUD) had H. pylori, and 22 (6 GU + 16 NUD) did 
not. Severe gastritis was found in 36% of subjects 
without H. pylori and 77% of subjects infected with H.
n
pylori (X = 8.64, p<0.01). Patients with severe
gastritis (regardless of the presence of H. pylori) had 
significantly higher PGE2 and PGI2 values than those with 
mild gastritis. No significant differences in PG values 
were found between subjects infected with H. pylori and 
those who did not have the organisms.
11.2. INTRODUCTION.
Both endogenous and exogenous PGs are thought to have 
a unique combination of favourable effects on the 
gastrointestinal mucosa (38,211,242-244). They inhibit 
acid secretion, are trophic to the gastric mucosa and are 
'cytoprotective’ against various experimental injuries. 
On the other hand, H. pylori has been associated with 
gastritis and peptic ulceration (138,159,245,246).
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However, the effect on endogenous PG synthesis of the 
presence of H. pylori remains unclear. The aim of this 
double-blind study is to assess gastric mucosal PG 
synthesis in patients with GU and NUD who have H. pylori 
compared to those who do not have the organisms.
11.3. PATIENTS AND METHODS.
11.3.1. Patients:
They were recruited between 1987 - 1988, having been 
referred for investigations of upper abdominal complaints. 
They were included if they were 18-75 years old, without 
any history of gastric surgery, and in the absence of 
concurrent infection or systemic illness. They were
excluded if their alcohol intake was heavy (more than 10 
units/week, one unit equals half pint or 1 measure of
spirit) or if they took ulcer healing agents, non­
steroidal anti-inflammatory drugs within a week, or 
antibiotics within a month of endoscopy. NUD was defined 
as the presence of upper abdominal symptoms for at least 
one month, normal upper gastrointestinal endoscopy or 
mucosal erythematous changes, normal upper abdominal
ultrasound, and without the intake of the drugs mentioned 
above. Patients with GU were included only if their 
ulcers were antral and benign as proved by histology. 
Being H. pylori positive meant that the organisms had to 
be seen on histology and grown by bacteriological methods 
in gastric biopsies taken from the study patients.
Informed consents were obtained from all patients, and the
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study was approved by the local Ethical Committee. 
Patients fasted for up to 12 hours prior to endoscopy and 
received 7.5, - 15 mg diazepam intravenously just before 
the procedure.
Fifty-two patients were initially entered in the 
study: 26 had GU, 15 males and 11 females with a median
age of 44 years and included 12 smokers. The other 26 
patients had NUD, 6 males and 20 females with a median age 
of 33 years and included 16 smokers.
11.3.2. Gastric biopsies and their disposition.
Seven endoscopic biopsies were obtained from each 
patient, four from the gastric antrum and three from the 
body, with 2 mm Olympus biopsy forceps. Antral biopsies 
were taken from sites approximately 5 cm from the pylorus. 
Biopsies from the gastric body were taken from the greater 
curve aspect. The above samples were disposed of as 
follows:
Single biopsies weighing 5-6 mg were taken at random 
from healthy looking mucosa in the antrum, at least 2 cm 
away from the ulcer edge in those with GU. They were 
immediately frozen in dry ice (-96°C) and stored at -70°C 
till the time of PG assay. Two biopsies from the antrum 
and two from the body were placed in 10% formalised saline 
for histopathological assessment. One specimen from each 
area was placed in 0.9% saline for bacteriological 
culture. The specimens were assigned for bacteriology or 
pathology at random.
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In addition to the above seven biopsies, an average 
of five other specimens were taken from the ulcer edge and 
base in order to exclude malignancy in patients with GU.
11.3.3. Identification of H. pylori.
Bacteriological culture techniques and histopathology 
were used to identify H. pylori, as described in Chapter 
4. In addition, the histological appearances were
broadly divided into un-inflamed/mild gastritis (normal or 
with minimal polymorphonuclear infiltration up to the 
lamina propria), or inflamed/severe gastritis (moderate to 
intense infiltration of the lamina propria, glands and 
crypts with neutrophils and polymorphonuclear cells) . 
Such arbitrary classification helps overcome the 
difficulty in finding biopsies absolutely devoid of 
inflammatory cells, that can subsequently affect PG 
synthesis and measurement (84,87).
11.3.4. Measurement of Prostaglandin Synthesis:
Frozen biopsies were thawed, weighed, washed for 5 
minutes in 0.5 ml of phosphate buffered saline and the 
supernatant was discarded to minimize measurements of PGs 
induced by trauma. Fresh buffer was added and biopsies 
were incubated for 30 minutes at 20°C and for another 30 
minutes at 37°C. Each time the supernatant was taken and 
added to an equal volume (1:1) of methyloximation agent 
(MOX) to stabilize the compounds synthesised (96) till the 
time of the radioimmunoassay. All samples were assayed 
in duplicate. Other details of PG assay are as described
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in Chapter 2. The results are expressed in ng PG/mg
protein contained in each biopsy after incubation. The 
protein was measured by the Lowry method (98). PGI2 and 
Thromboxane A2 were measured as their stable metabolites, 
6-oxo-PGF-l and Thromboxane B2 (TXB2) respectively. All 
assessments were performed under double-blind conditions, 
using code numbers.
11.3.5. Statistical Analysis:
o
The Mann-Whitney and X tests were used where
appropriate.
11.4. RESULTS.
Four patients with GU were found to be positive for 
H. pylori on histology but negative on bacteriological 
examination; they were dropped from the study as, by
definition, subjects had to be positive or negative for H. 
pylori both by histology and bacteriology. Data on the 
remaining 48 patients (22 GU and 26 NUD) are shown in
Table 8 and Figures 18-20.
Patients positive for H. pylori had more severe
gastritis (active chronic gastritis with intense 
polymorphonuclear infiltration, see methods): 20 patients
(77%) compared to 8 (36%) in the H. pylori negative group 
(X^=8.64, p<0.01). In addition, severe antral gastritis 
was present in 8 patients (31%) with NUD and 20 GU cases, 
91% of the total GU (X^=16.93,p<0.001). The proportion of 
patients with severe gastritis in the GU subgroup (91%) 
was higher than that in the group of patients with H.
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TABLE 8
CHARACTERISTICS OF PATIENTS POSITIVE OR NEGATIVE 
FOR HELICOBACTER PYLORI, GASTRIC ULCERS AND 
NON-ULCER DYSPEPSIA.
H. pylori NEGATIVE H. pylori POSITIVE
GU NUD
Total
HP
Negative
GU NUD
Total
HP
Positive
Total Number 
of Patients 6 16 22 16* 10 26
Sex:
Males 5 5 10 8 1 9
Females 1 11 12 8 9 17
Age (years) 50 38 46 46 28 37
Number of 
Smokers 3 10 13 9 6 15
Gastritis: 
Mild 1 13 14 1 5 6
Severe 5 3 8 15 5 20**
Significant rise: * X2=5.4, p<0.05 (compared to H. pylori
negative GU)
** X2=8.64, p<0.01 (compared to H. pylori
negative severe gastritis)
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pylori as a whole (77%) but the difference was not 
statistically significant (X^=2.4, 0.1<p<0.25).
Gastric mucosal PGs were found to be greater in the 
presence of severe antral gastritis or ulceration when the 
presence of H. pylori was disregarded (Figures 18-20). 
There was a tendency for PG values to be elevated in H. 
pylori positive group and subgroups (Figures 18-20), but 
such elevation did not reach the degrees of statistical 
significance.
11.5. DISCUSSION.
H. pylori was found in 73% of GU patients in this 
study. This is comparable to previous findings in this 
field (141,142). Also, 38% of patients with NUD had H. 
pylori detected in their gastric biopsies. Rokkas et al. 
(171) isolated H. pylori from 45% of subjects with NUD. 
Their definition of NUD was similar to the one used in 
this study. The importance of identifying this
condition, NUD, stems from the possibility that it might 
respond to treatment with bismuth compounds (172).
The mechanism of interaction between H. pylori and 
local host defences has been the subject of numerous 
studies because of its importance in understanding the 
pathogenesis and treatment of H. pylori-related damage. 
Such interaction is thought to involve a variety of 
factors including the state of gastric acid secretion 
(144,173-178), the urease activity (159,179,180), the 
possibility of cytotoxicity (188), antibody formation and
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complement activation (182).
It has not been clear what happens to endogenous 
gastric mucosal PG synthesis in the presence of H. pylori, 
which is capable of producing the interactions involving 
the above-mentioned factors. The findings of this study 
are in agreement with the results of previous studies that 
showed increased PG synthesis in the presence of gastritis 
and GU (87), regardless of H. pylori status. The total 
amount of PG produced in the presence of gastritis is 
probably equal to PG synthesized by the mucosal cells plus 
PG produced by the inflammatory cells: human neutrophils
and macrophages both have the capacity to synthesize PG 
(84). Since H. pylori is associated with a higher
prevalence of severe gastritis, one would expect, at least 
in theory, that PG values would be significantly greater 
in the H. pylori positive groups and subgroups. This, 
however, was not observed in this study, and it is 
somewhat surprising. In these circumstances, it might be 
tempting to speculate on the possible presence of some 
form of defective PG production, but such defect is not 
confirmed by these findings.
Alternatively, it could be argued that the 
differences in PG values in patients with or without H. 
pylori might become more discernible if greater numbers of 
patients were studied. It is also worth noting that this 
study investigated PG synthesis in relation to the 
presence or absence of H. pylori, and not in relation to 
the density of the organisms. This is because I share
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the belief that H. pylori infection is patchy within the 
stomach, and accept that the density of H. pylori could 
have influenced the results. In addition, it might be 
necessary to assess PG synthesis in the presence of H. 
pylori in patients with duodenal ulcers; however, such an 
assessment could become complicated by the difficulty in 
finding duodenal ulcer patients who are H. pylori 
negative, and by gastric metaplasia.
These findings might have some therapeutic 
implications. Recent studies have demonstrated the
beneficial effects of colloidal bismuth subcitrate and 
antibiotics (162,172,247) in the treatment of H. pylori- 
related conditions. Colloidal bismuth subcitrate was
also shown to stimulate gastric and duodenal alkaline 
secretion through a PG- dependent mechanism (248). The 
same agent was later found to have a protective action on 
aspirin-induced gastric microbleeding and this protection 
occurred despite a marked suppression of mucosal PG 
production (249). In the light of these findings, the 
results of this study would suggest that for an agent to 
be effective in the treatment of H. pylori related 
gastritis and GU, its bactericidal activity is more 
critical than its effect on endogenous PG synthesis. In 
other words, the primary aim of treatment should continue 
to be that of eradicating the organism, and not 
necessarily to increase PG synthesis, since this is not 
significantly affected, as shown by the above results.
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CHAPTER 12
12. THE INTERACTION BETWEEN HELICOBACTER PYLORI CULTURE 
FILTRATE AND INDOMETHACIN • EFFECTS ON THE 
INTEGRITY OF THE HUMAN GASTRIC ANTRAL MUCOSA AND ITS 
PROSTAGLANDIN E2 PRODUCTION IN VITRO.
12.1. SUMMARY.
Histopathological methods and radioimmunoassay were 
used to assess the microstructure and prostaglandin E2 
production by paired specimens of human gastric antral 
mucosa; the specimens were studied after 48 hours of 
incubation in base-line tissue culture medium, 
Helicobacter pylori culture filtrate, Helicobacter pylori 
culture control fluid, indomethacin, and Helicobacter 
pylori culture filtrate plus indomethacin. When applied 
alone, the filtrate did not affect the structure of the 
mucosal tissue or its PGE2 synthesis. In the overall 
group (n=21), specimens incubated with the mixture of 
Helicobacter pylori filtrate and indomethacin had a median 
histological grade of 1 and prostaglandin E2 of 29 pg/mg 
tissue, compared to 2 (p=0.04) and 60 (p=0.0007)
respectively, in specimens incubated with indomethacin 
alone.
These results indicate that an interaction may exist 
between indomethacin and a factor contained in 
Helicobacter pylori culture filtrate. Such interaction 
is damaging to the human gastric antral mucosa, and its
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understanding might have therapeutic implications.
12.2. INTRODUCTION.
The evidence for the pathogenicity of Helicobacter 
pylori (H. pylori) has in most cases been epidemiological 
in nature and was based on the association between the 
presence of bacteria and various types of peptic disease 
(137,162). Experiments involving self-inoculation with 
the organisms (144,176) provided very useful information, 
but their use is severely limited by the understandable 
ethical objections to giving any form of bacteria to human 
volunteers. Recently, it has been reported that H.
pylori can produce a factor capable of causing cytopathic 
changes in mammalian cell lines (188), and inhibiting acid 
secretion by rabbit parietal cells (189). The effect of 
this factor on the human gastric mucosa has not been 
studied, and its possible interaction with another mucosal 
damaging agent in common use, indomethacin, is not known. 
Therefore, this study aimed at investigating the 
possibility of such interaction using mucosal histology 
and PGE2 production as end points in biopsy specimens 
obtained from subjects presenting with dyspepsia.
12.3. PATIENTS, MATERIALS AND METHODS.
12.3.1. Patients:
Patients were recruited from the Gastroenterology 
outpatient clinic after presenting with upper abdominal 
pain, nausea, vomiting or heartburn, if they were 18-70
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years old, and after giving informed consent. They were 
excluded if they took non-steroidal anti-inflammatory 
drugs or ulcer healing agents within a week, or 
antibiotics within a month of performing the endoscopy. 
They were also excluded if they had a history of previous 
gastric surgery, systemic illness or infection.
Twenty two subjects were studied: 11 positive and 11
negative for H. pylori. In each sub-group, the first 11 
patients found to satisfy the inclusion criteria were 
accepted.
12.3.2. Gastric Biopsies:
These were taken from healthy looking mucosa in the 
gastric antrum, about 3-5 cm proximal to the pyloric ring. 
The antrum was chosen because it is considered the 
commonest site for both H. pylori colonization (137,162) 
and the side effects of non-steroidal anti-inflammatory 
drugs (227, Chapter 9). A total of seven biopsies
weighing 7-10 mg each, were taken from each subject. Two 
were used for detecting the presence of H. pylori by both 
bacteriology and histology as described in Chapter 4. 
The remaining five were incubated in 24-well plates (1 
biopsy/well) in order to study their response to the test 
reagents (see below). Biopsies were allocated to
various procedures at random.
12.3.3. Collection and concentration of H. pylori
filtrate, control fluid, and gastric tissue
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culture fluid.
These were all prepared as described in Chapter 4.
12.3.4. Incubation of gastric tissue with test agents:
Seven antral biopsies were taken,at endoscopy, from 
each patient as mentioned above. Those allocated for 
incubation (5 specimens) were immediately immersed in 2 ml 
of gastric culture fluid. The fluid was discarded to 
remove the debris, and the biopsies were weighed and 
transferred to 24-well plates that had small pieces of 
capillary matting at their bases to reduce evaporation of 
the culture fluid. Each well contained one single
biopsy, 500 ul of gastric culture fluid and 50 ul of 
homologous citrated plasma that was freshly prepared to 
act as a source of growth factors. One well was left 
with these ingredients only, to act as a base-line. In 
addition, the other 4 wells contained one of the following 
per well: 50 ul filtrate (1.6 Units as defined above), 50
ul H.pylori culture control fluid, 7.4 ug indomethacin in 
50 ul buffer, and 50 ul filtrate plus 7.4 ug indomethacin. 
An extra 50 ul gastric culture fluid was added to the 
base-line well to make a final volume of 600 ul per well. 
The amount of indomethacin used was previously found to be 
capable of inhibiting PG synthesis in gastric biopsies. 
After the addition of various agents the wells were 
covered, sealed with micropore and placed in an incubator 
set at 37°C and 5.6% CO2 . After 24 hours the medium was
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removed and fresh culture fluid and agents added. 
Incubation was continued for another 24 hours (total of 48 
hours); this is because of the previous finding (188) that 
the cytotoxic activity was maximal by 48 hours. At the 
completion of incubation the medium was removed and mixed 
with an equal volume of methyloximating agent (MOX)(96) to 
stabilise PG compounds till the time of PG measurements.
The biopsies were weighed, given code numbers to
facilitate randomization, and fixed in formalin-saline in 
order to grade their histology.
12.3.5. Assessment of post-incubation tissue histology:
Histopathological methods were used to monitor tissue 
viability. This approach was used in preference to other 
techniques such as tritiated leucine incorporation 
because this study dealt with biopsies composed of
numerous cell layers and not with single cells or
monolayers. In the latter method, the label would be 
taken up only by the superficial layers. Sections were 
made at 3 levels in each biopsy. Histological scoring was 
performed by noting the proportion of intact or
regenerative tissue in comparison to a base-line specimen 
that did not undergo incubation. It was assumed that 
cells that looked microscopically intact were viable. 
Grading was as follows: Grade 0 meant that no intact
epithelium was seen, Grade 1: 1-10% of the epithelium was
intact, Grade 2: 11-30%, Grade 3: 31-60%, Grade 4: 61-90%, 
and Grade 5: 91-100% of the epithelium was maintained.
The histologist was blinded to the study specimens by the
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use of code numbers.
12.3.6. Prostaglandin Measurements:
PGE2 was measured by radioimmunoassay in the 
methyloximated medium obtained after the second 24-hour 
incubation period; this is because the medium from the 
first period was thought to contain large amounts of PG 
compounds induced by trauma. All samples were assessed 
in duplicate and had code numbers to facilitate 
randomization. The radioimmunoassay for PGE2
described in Chapter 2. The results were expressed in
pg PGE2 /mg of post-incubation tissue weight.
The study was approved by the local Ethics Committee.
12.3.7. Statistical Analyses:
o
The Wilcoxon's, Mann-Whitney, Kruskall-Wallis and X 
tests were used where appropriate.
12.4. RESULTS.
One subject was dropped from the final analysis 
because of mild impairment in his liver function tests. 
The characteristics of the remaining 21 subjects are shown 
in Table 9. Patients described as being positive for H. 
pylori were found to have the organisms in specimens 
assessed by both histology and bacteriology. They were 
comparable to the negative group as far as age and sex are 
concerned. The positive group included a greater 
proportion of smokers and of cases with active chronic 
superficial gastritis. PGE2 and viability histological
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TABLE 9.
GENERAL CHARACTERISTICS OF THE STUDY SUBJECTS.
H. pylori H. pylori 
Total positive negative
Median age (years)
Sex: Males
Females
Smokers
Endoscopic findings:
a. Normal
b. Oesophagitis
c. Hiatus Hernia
d. Gastric Ulcer
e. Duodenal Ulcer
Base-line Histology:
a. Normal
b. Active chronic 
superficial gastritis
c. Chronic atrophic 
gastritis
(n=21) (n=10) (n=ll)
41 41 42
9 4 5
12 6 6
12 8 4
13 4 9
2 1 1
2 2 0
1 1 0  
3 2 1
6 0 6
14 10* 4
1 0  1
* significant rise compared to subjects negative 
for H. pylori:
X2=9.3, df=l, 0.001<p<0.01
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Fig. 21. PGE2 produced by gastric biopsies incubated
with H. pylori culture filtrate, indomethacin, 
mixture of H. pylori culture filtrate and 
indomethacin?and the control fluids.
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Fig. 22. Gastric mucosal microstructural (viability)
scores after incubation with H. pylori culture 
filtrate, indomethacin, mixture of H. pylori 
filtrate and indomethacin1and the control fluids.
grades are shown in Figures 21 and 22. Specimens
incubated in the presence of a mixture of indomethacin and 
H. pylori filtrate had the lowest histological scores, 
and their PGE2 values were even lower than those produced 
by specimens incubated with indomethacin alone. Similar 
findings were noted after subgroup analysis of the data on 
subjects who were found to be positive or negative for H. 
pylori at base-line. In addition, it was found that 
base-line values of PGE2 in patients with active chronic 
gastritis, 895 (658-1182) pg/mg tissue, median
(interquartile ranges), were greater than those of
patients without gastritis, 353 (237-440) pg/mg tissue,
p=0.003 (Mann-Whitney U-test). The differences in PGE2 
values and viability grades between smokers and non- 
smokers, or between patients positive or negative for H. 
pylori did not reach the degrees of statistical
significance.
12.5. DISCUSSION.
This study demonstrates that biopsies incubated in 
the presence of a mixture of H. pylori culture filtrate 
and indomethacin had lower PGE2 values than those exposed 
to indomethacin only. This could be due to a combination 
of cyclo-oxygenase enzyme inhibition by indomethacin and 
the reduction in the mass of viable cells in gastric 
tissue subjected to the above mixture, as indicated by the 
histological grading. On the other hand, the inhibition 
of PGE2 by indomethacin alone is largely due to its direct
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effect on the enzymatic system involved in PG synthesis.
The fact that indomethacin suppressed PGE2 formation 
is not surprising but it confirms that PGE2 synthesis was 
permitted in the other specimens that were not subjected 
to this NSAID.
The results of this study could have been influenced 
by patients age, sex, smoking, the presence or absence of 
gastritis or H. pylori in their base-line specimens. It 
is believed that correction for the effects of these 
factors was achieved by studying multiple specimens taken 
from each patient and by the use of paired analysis. The 
finding that H. pylori was associated with a significant 
number of cases with active chronic gastritis is in line 
with previous studies in this field (137,162). Also, the 
association between gastritis and the rise in PGE2 , 
regardless of H. pylori status, is in agreement with the 
results of investigations performed in this Thesis 
(Chapter 11) and elsewhere (86,87).
In general, higher grades of viability could not be 
achieved in the study groups and this highlights the 
difficulties encountered in trying to keep multiple layers 
of gastric tissue alive for a relatively long time. It 
was aimed to culture the tissue, as far as possible 
under physiological circumstances, for a period of 48 
hours, the optimal time for cytotoxic activity (188,250). 
To incubate for shorter periods may ensure a greater 
degree of viability, but this would not be representative.
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The relationship between bacterial toxins and PG 
synthesis is still poorly understood. H. pylori culture 
filtrate alone did not have any significant effect on the 
integrity of gastric antral tissue or its PGE2 production 
over the incubation period used in this study. Other 
bacterial toxins, the lipopolysaccharides, were previously 
found to increase intestinal PG synthesis in the 
laboratory animal even after their application for short 
periods (251,252). This could be due to species-specific 
responses and to the structural differences between these 
agents. The precise structure of the "toxic" factor in 
H. pylori culture filtrate is not known, although it is 
thought to be a protein as suggested by a recent study 
(189) and Chapter 13.
The amount of "toxic" factor contained in the 
culture filtrate used in this study was determined by 
titrating its cytopathic activity against Vero cells. It 
is not known whether such concentration is comparable to 
that found in the gastric mucosa jun vivo. It did not 
affect the viability of gastric tissue in this study, and 
this confirms previous results in mammalian cells (188). 
Such a finding could be attributed to the possibility that 
this study used a relatively low concentration of the 
filtrate. It is, however, interesting to find that, even 
at this concentration, it was possible to detect evidence 
of an interaction with indomethacin.
The understanding of this interaction between 
indomethacin and H. pylori culture filtrate might have
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therapeutic implications if its presence could be 
confirmed by in vivo studies. It could be justifiable to 
ask whether the results of this study could explain, at 
least in part, the higher incidence of complications 
related to non-steroidal anti-inflammatory drugs (NSAIDs) 
in the elderly patient (100,108,116) who, at the same 
time, are believed to have a higher prevalence of H. 
pylori colonization (196,253). The role of H. pylori is 
not clear in such cases, and other factors have been 
suspected. These include the continuing increase in
NSAID prescribing (100), the possible role of diet (117), 
and the effect of the cohort phenomenon (118).
The possible role of bacteria in increasing NSAID 
toxicity was previously described in experiments involving 
the intestine of laboratory animals. It was observed 
that the ulcerogenic effect of NSAIDs could be reduced by 
antibiotic treatment (135). Germ-free animals were also 
found to be resistant to indomethacin-induced lesions 
(136). It remains to be seen whether the eradication of 
H. pylori would reduce the frequency, or at least the 
degree of NSAID-induced gastric damage.
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CHAPTER 13.
13. INHIBITION OF GASTRIC CYCLIC AMP PRODUCTION BY 
HELICOBACTER PYLORI PROTEIN.
POSSIBLE INVOLVEMENT OF MUCOSAL PROSTAGLANDIN E2-
13.1. SUMMARY.
Although H. pylori has been linked to the development 
of peptic ulceration, its effect on gastric physiology is 
not clear. H. pylori protein has been shown to inhibit 
gastric acid secretion in rabbit parietal cells. Cyclic 
AMP acts as a second messenger in several physiological 
activities in the stomach, including acid secretion. 
Cyclic AMP is also known to interact with PGE2 in various 
tissues including the gastric mucosa. This study
investigated the effect of H. pylori protein on c.AMP and 
PGE2 production by incubates of human gastric fundic 
mucosa. Biopsies were taken from 12 subjects: 5 males
and 7 females, median age 52 years. At 24 hours,
specimens incubated in the control fluid had a median 
c.AMP value of 81 pmol/mg protein, compared to 28 (p<0.05) 
in H. pylori protein, 155 (p<0.006) in histamine, and 23 
(p<0.05) in histamine plus H. pylori protein. A similar 
trend was observed at 48 hours. Although H. pylori 
protein had no direct effect on mucosal PGE2, it 
intensified the inhibitory effect of indomethacin and 
prevented the stimulatory effect of histamine on both PGE2 
and c.AMP production. Given the role of c.AMP in various 
physiological responses, these results suggest that acute
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exposure to H. pylori protein might alter those functional 
aspects of the human gastric mucosa mediated by c.AMP. 
Assuming that PGE2 mediates such effect, its role would 
appear to be either partial or indirect.
13.2. INTRODUCTION.
The precise mechanism of interaction between 
Helicobacter (H.) pylori and the gastric mucosa is not 
fully understood. It is increasingly accepted that H. 
pylori produces a factor which might be comparable to 
other bacterial toxins. The nature of this factor and 
the range of its activities have been the subject of 
several studies in recent years. Leunk et al. (188) 
demonstrated that H. pylori culture filtrates induced 
cytopathic changes in Vero (mammalian) cells. Cave and 
Vargas (189) later showed that a protein isolated from H. 
pylori culture filtrates could reduce acid secretion by 
rabbit parietal cells. As in many other tissues,
receptors for the control of gastrointestinal mucosal 
function can be divided into two major classes: those
which trigger the production of c.AMP and those which 
initiate inositol phospholipid turnover, calcium 
mobilisation, and frequently arachidonic acid release and 
cyclic GMP production (254,255). Cyclic AMP appears to
have a major role in controlling gastric acid secretion
(256-259). This role can be influenced by the
interaction thought to exist between c.AMP, prostaglandins
(PGs), and histamine (260-264). Reduced acid secretion
was noted when H. pylori organisms were ingested (144,176)
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and when H. pylori protein was applied to parietal cells 
(189). It is not known whether an interaction exists 
between H. pylori protein, c.AMP, histamine, or mucosal 
PGE2 . This study aimed at investigating the possibility 
of such an interaction by measuring the generation of 
c.AMP and PGE2 in response to H. pylori protein with or 
without histamine, in vitro.
13.3. PATIENTS AND METHODS.
13.3.1. Patients:
Twelve subjects were studied. They included 5 males 
and 7 females, median age 52 years. Five were smokers. 
They all presented with upper abdominal pain, nausea, 
vomiting, or heartburn. Patients were excluded if they 
took any medications within a week of performing the 
endoscopy, or if they had any other illness.
13.3.2. Gastric Biopsies:
Twelve biopsies, weighing 3-5 mg each, were taken 
from the gastric fundus of each patient, within 2-5 cm. of 
the gastro-oesophageal junction. They were grouped in 
pairs, and each pair was kept fresh at 4°C in 4 ml of 
tissue culture fluid (see below), until the time of 
incubation 3 hours later. The fluid used during this 
period was discarded to minimise measurement of PGs 
induced by trauma. Two more biopsies were taken to
detect the presence of H. pylori in each patient by 
both histology and bacteriology, as described in Chapter 
4.
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13.3.3. Isolation of H. pylori protein, preparation of 
H. pylori culture control fluid and gastric 
tissue culture medium:
As described in Chapter 4.
13.3.4. Incubation of gastric biopsies:
Six pairs of fundic biopsies, taken from each 
subject, were incubated inside 24-well plates containing 
small pieces of capillary matting to reduce evaporation of 
the culture media. Each well contained one pair of
biopsies, 800 ul of gastric tissue culture medium, and 100 
ul of homologous citrated plasma which was freshly 
prepared to act as a source of growth factors. In
addition, one of the following was added per well: (A)
100 ul H. pylori protein, (B) 100 ul H. pylori control
fluid, (C) 7.4 ug indomethacin, (D) 100 ul H. pylori 
protein plus 7.4 ug indomethacin, (E) 10 x 10“  ^ molar
histamine, (F) 10 x 10“  ^molar histamine, plus 100 ul H. 
pylori protein. The wells were then sealed and incubated 
at 37°C with 5.6% CC>2 . Indomethacin was used in order to 
inhibit PGE2 production, and as a result to prove that 
PGE2 synthesis was permitted in specimens not exposed to 
indomethacin. After 24 hours the supernatants were
collected and fresh fluids and materials added. 
Incubation was continued for another 24 hours. The two 
biopsies within each well were then removed: one was
immediately frozen at -20°C for intracellular c.AMP 
measurements, and the other fixed in formalin/saline for
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post—incubation histological assessment. The supernatants 
yielded from individual wells at the end of each 24 hour 
period were divided into 2 halves. The first was frozen 
at -20°C for c.AMP measurement. The other half was added 
to an equal volume of methyl-oximating (MOX) agent (96) to 
stabilise PG compounds till the time of PG measurement.
13.3.5. Measurement of Cyclic AMP:
Cyclic AMP was measured by radioimmunoassay in both 
supernatants and the corresponding biopsy specimens of 
each well. Single biopsies were homogenized in 1.5 ml of 
a buffer composed of the following: Tris HC1 50 mmol/1, 
mercaptoethanol 16 mmol/1, isobutylmethylxanthine 1 mmol/1 
and HC1 0.1 mmol/1. The homogenate was sonicated for 3 
minutes and then mixed with 50 ul of 1M NaOH. 500 ul of 
the resulting solution was taken for protein measurement 
as described by Lowry (98). Another 500 ul of the same 
solution was lyophilised and dissolved in 50 mM acetate 
buffer, pH 4.8, prior to acetylation with 
triethylamine/acetic anhydride (2:1) and estimation of 
c.AMP by radioimmunoassay. Results were expressed as 
pmol c.AMP/mg protein. Values\ obtained from the
supernatant of the first incubation period were identified 
as 24 hour c.AMP. Values related to the second
incubation period in supernatant plus biopsy homogenates 
were identified as 48 hour c.AMP. All specimens were 
assayed in duplicate, and at random, using code numbers. 
The c.AMP antisera have been described previously (265). 
The assay has a minimum detection limit of 30 pmol/1 and a
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between batch coefficient of variation of 10-15% over the 
working range.
13.3.6. PGE2 measurement:
PGE2 was measured by radioimmunoassay in the 
methyloximated supernatant as described in Chapter 2. 
The results were expressed in pg PGE2 /mg of post­
incubation tissue weight. Code numbers were used to 
facilitate randomization.
13.3.7. Statistical Analyses:
Paired analysis was carried out using the Wilcoxon’s 
signed ranks and the Kruskall-Wallis tests where 
appropriate.
The study was approved by the Local Ethics Committee.
13.4. RESULTS.
Endoscopic findings in the study subjects included 1 
gastric ulcer, 5 duodenal ulcers and 6 normal findings. 
Histological examination of un-incubated baseline 
specimens showed that 11 subjects had features of chronic 
superficial active gastritis. These all had H. pylori 
detected in their biopsies by both histology and 
bacteriology. The remaining subject did not have H. 
pylori, and the histology of his baseline biopsy was 
normal. Comparing the histological appearances of
gastric biopsies after 48 hours of incubation to baseline 
un-incubated specimens, it was found that 30-60% of 
epithelial cells were maintained, regardless of the
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contents of the culture media in 5 out of 6 wells. 
However, only 10-30% of cells within specimens incubated 
in the mixture of H. pylori protein and indomethacin were 
maintained (p<0.05). This histological comparison
between biopsies before and after incubation was taken as 
a rough guide to tissue viability during incubation, as 
discussed in Chapter 12.
Gastric c.AMP and PGE2 at 24 and 48 hours are shown 
in Figures 23-26. When applied alone, H. pylori protein 
suppressed c.AMP generation but did not seem to affect 
that of PGE2 . Also, the synthesis of both c.AMP and 
PGE2 was inhibited by indomethacin and stimulated by 
histamine. The addition of H. pylori protein appeared to 
intensify the effect of indomethacin and inhibit that of 
histamine.
13.5. DISCUSSION.
Cyclic AMP measured in this study probably represents 
the total amount released by all cellular elements 
contained in the fundic mucosal specimens. The duration 
of the incubation period was intended to allow H. pylori 
protein to permeate through the superficial and inner 
layers of gastric tissue. The values of c.AMP and PGE2 
reported do not necessarily equal the overall amounts 
synthesised during 24 or 48 hours, because of the 
instability of these compounds. They probably represent 
c.AMP and PGE2 produced within minutes before incubation 
was terminated.
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Fig. 23. Gastric c.AMP produced at 24 hours of
incubation with H. pylori, indomethacin, 
histamine, mixture of H. pylori protein 
and indomethacin, mixture of H. pylori 
protein and histamine, and control fluid.
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Fig. 24. Gastric PGE2 produced at 24 hours of
incubation with H. pylori, indomethacin, 
histamine, mixture of H. pylori protein 
and indomethacin, mixture of H. pylori 
protein and histamine, and control fluid.
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Fig. 25. Gastric c.AMP produced at 48 hours of
incubation with H. pylori, indomethacin, 
histamine, mixture of H. pylori protein 
and indomethacin, mixture of H. pylori 
protein and histamine, and control fluid.
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Fig. 26. Gastric PGE2 produced at 48 hours of
incubation with H. pylori, indomethacin, 
histamine, mixture of H. pylori protein 
and indomethacin, mixture of H. pylori 
protein and histamine, and control fluid.
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In addition to its role in gastric acid secretion 
(256-259), c.AMP is thought to be involved in many other 
activities of the gastrointestinal tract. Several in 
vitro studies have demonstrated that c.AMP or its 
derivatives exerted a stimulatory effect on pepsinogen 
secretion (266-268), bicarbonate transport (269), and 
mucus glycoprotein synthesis (270). Elevation of tissue 
c.AMP content was associated with vasodilator activity 
induced by a variety of agents; exogenously applied c.AMP 
dilated the canine mesenteric circulation (271). By
interfering with c.AMP production, it is possible to 
speculate that H. pylori protein might alter at least some 
functional aspects of the human fundic mucosa.
Assuming that the parietal cell c.AMP was also 
suppressed, our results might explain the initial 
hypochlorhydria observed following acute exposure to H. 
pylori (144,176). In support of this assumption is the 
recent observation that stimulation of histamine H2 
receptors activates adenylate cyclase in the cell, thereby 
increasing its c.AMP content, while stimulation of 
histamine H-^ receptors activates phosphinositidase C to 
produce diacylglycerol and inositolphosphates (272). 
This study showed that H. pylori protein suppressed the 
synthesis of c.AMP and the stimulatory effect of histamine 
on its generation. These two activities are thought to 
involve histamine H2 receptors, which in turn mediate acid 
secretion (258,259,272).
Little is known about the effects of bacterial toxins
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on the human gastric mucosal c.AMP. Most studies have 
investigated their effects on the intestinal mucosa of 
laboratory animals. Unlike H. pylori protein, the 
enterotoxins of Salmonella and Cholera were shown to
increase mucosal c.AMP production (273,274). This might 
help explain the difference in the degree and type of 
toxicity between these organisms.
When applied alone, H. pylori protein did not seem to 
affect mucosal PGE2 values, which is consistent with the 
findings of Chapter 12 using H. pylori culture filtrate. 
It, however, intensified the inhibitory effect of
indomethacin and prevented the stimulatory effect of
histamine on PGE2 formation. PGE2 was previously found to
increase gastric c.AMP synthesis (275,276), although some 
workers (260,261) believe that histamine-stimulated 
production of c.AMP was suppressed by PGE2 or its
analogues in isolated canine parietal cells. The
mechanism by which PGs increase c.AMP formation is thought 
to involve their receptor interaction with stimulatory G 
proteins (receptor associated GTP-binding proteins) and 
adenylcyclase; under some circumstances PGs and other
eicosanoids may interact with alternate receptors and 
activate inhibitory G proteins to prevent c.AMP production 
(277). The simultaneous inhibition by indomethacin of
both PGE2 and c.AMP production in this study and the
parallel intensification of this by H. pylori protein 
might suggest some role for PGE2 in mediating the
interaction between H. pylori protein and c.AMP, given the
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known effect of PGE2 on c.AMP synthesis. This is
further supported by the finding that H. pylori protein
interfered with the stimulatory effect of histamine on 
both PGE2 and c.AMP production. Since PGE2 synthesis 
was not directly inhibited by H. pylori protein, any role 
it may have in mediating the effect of H. pylori protein
on c.AMP generation would appear to be either partial or
indirect.
In conclusion, acute exposure to H. pylori protein
lowers gastric mucosal c.AMP and prevents its stimulation 
by histamine. This may be mediated partially or
indirectly by mucosal PGE2. These findings might help 
clarify further the interaction between H. pylori protein 
and the human gastric mucosa.
SECTION 5.
GENERAL DISCUSSION AND CONCLUSIONS.
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CHAPTER 14.
14. GENERAL DISCUSSION AND CONCLUSIONS.
The studies included in this Thesis relate to the 
ongoing debate about the importance of three major 
factors: PGs, NSAIDs, and H. pylori in the pathogenesis
of peptic ulcer disease. The background of this Thesis, 
discussed in Section 1, reviews the current evidence of 
the involvement of these factors in peptic ulceration. It 
also covers the contribution made by this Thesis to the 
understanding of some aspects of peptic ulcer disease and 
the methodology used in its research.
Some of the major methodological considerations in PG 
research are reviewed in Chapter 2. Another important 
issue in this context, which received little attention in 
the past, is investigated in Chapter 6. It relates to 
the importance of tissue handling and how to care for 
biopsies prior to carrying out the PG assays.The basic 
question of whether to incubate biopsies fresh or after 
freezing them and the consequences of either option are 
explained. It is obvious therefore that fresh specimens 
follow a different behaviour from frozen ones, probably 
because of the ultrastructural changes caused by freezing. 
The effect of low temperature on tissue functions is not 
new; unlike other functions which are adversely affected,
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PG production seems to be enhanced because of the 
disintegration of cell membranes.
Subsequent sections investigate PG synthesis in 
response to a variety of factors including diet, duodenal 
ulceration, naproxen, etodolac, gastric ulcers, gastritis, 
non-ulcer dyspepsia, H. pylori, H. pylori culture filtrate 
and H. pylori protein. In addition, the interaction 
between H. pylori culture filtrate and indomethacin, and
the effect of H. pylori protein on gastric c.AMP 
production are investigated.
The important points can be summarized as follows:
1. As mentioned above, gastric and duodenal biopsies
incubated after being frozen can produce more PGE2 and 
PGI2 than fresh specimens. Also, for workers wishing to 
homogenize their tissues, freezing seems to be both 
convenient and effective in homogenizing the tissues 
before PG assays are carried out. Tissue sampling should 
be standardized within the individual experiment in order 
to minimize the possible sources of variation in PG 
results.
2. Diets rich in fish oil, evening primrose oil and 
olive oil can increase gastric PGE2 synthesis as shown in 
rats. Animals fed on fish oil diet tend to have lower PG 
values than the other diets, possibly due to the
competition between the individual fatty acid components
of each oil. Human studies in this field may be
worthwhile, as this may help understand the nutritional
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values of some commonly used oils, olive oil in 
particular, and their effect on the incidence of peptic 
ulceration.
3. There is no evidence that duodenal ulceration is 
associated with defective synthesis in PGE2 , PGl2 > or 
TXB2 . No such defect is found in gastric ulcers either. 
(Chapter 11). This might help explain, at least in part, 
the disappointing results of using so called 
"cytoprotective" doses of PG analogues in the treatment of 
peptic ulcers, especially those unrelated to NSAIDs.
4. One of the new NSAIDs, etodolac, seems to have a 
similar antiarthritic activity to the well established 
naproxen. The gastroduodenal side effects of these two 
agents are different, however, since naproxen resulted in 
worse endoscopic scores than etodolac. The endoscopic 
abnormalities detected after 4 weeks of treatment are 
mostly asymptomatic. This highlights the unreliability 
of patients symptoms as a means of monitoring NSAID side 
effects on the gastric mucosa.
5. Unlike most previous studies that investigated the 
effect of NSAIDs on gastric and duodenal PG synthesis, 
evidence is shown in this Thesis that not all NSAIDs 
suppress PG production. Etodolac appears to have no 
effect on gastric or duodenal PGs, while naproxen 
suppresses gastric PGE2 and duodenal PGE2 and PGI2 * 
These differences between the two agents become clear only 
after patients are grouped according to the drug they
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received and with the advantage of knowing base-line PG 
values. These aspects of the study are recommended for 
the proper evaluation of the rest of NSAIDs.
In line with findings of other studies, H. pylori was 
associated with a high prevalence of active chronic 
gastritis and gastric ulcers. In patients with gastric 
ulcers and non-ulcer dyspepsia, the presence of H. pylori 
in gastric tissue is not associated with a significant 
rise in PG values, which would normally take place in 
cases of gastritis regardless of H. pylori. The total 
amount of PGs measured is probably equivalent to PGs 
produced by the gastric mucosa and those synthesised by 
the inflammatory cells. The neutrophils are usually
present in abundance in cases of H. pylori-induced 
gastritis, as shown by the histological part of the study 
in Chapter 11. The failure of PGs to rise in the
presence of H. pylori might encourage speculation about 
the possible presence of a defect in PG synthesis at the 
level of the mucosal cells, the neutrophils, or both.
7. This Thesis presents evidence showing that an 
interaction may exist between H. pylori culture filtrate 
and indomethacin, in vitro. Such interaction appears to 
be damaging to the gastric antral mucosa. Specimens
incubated in a mixture of H. pylori culture filtrate and 
indomethacin produce less PGE2 and have lower histological 
scores than those incubated with indomethacin alone.
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8. A protein isolated from H. pylori culture filtrate 
(H. pylori protein) is shown to reduce c.AMP production by 
the gastric fundic mucosa in vitro. It also prevents the 
stimulatory effect of histamine on both PGE2 and c.AMP 
formation, and interacts with indomethacin in a manner 
similar to that of H. pylori culture filtrate. This 
might suggest that H. pylori protein could influence at 
least some gastric activities in which c.AMP acts as a 
second messenger.
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